

Zoetis Inc.
Form 10-Q
November 13, 2013
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 29, 2013
or
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

.. For the transition period from _____ to _____

Commission File Number: 001-35797

Zoetis Inc.

(Exact name of registrant as specified in its charter)

| | |
|---|--------------------------------------|
| Delaware | 46-0696167 |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
| 100 Campus Drive, Florham Park, New Jersey | 07932 |
| (Address of principal executive offices) | (Zip Code) |
| (973) 822-7000 | |
| (Registrant's telephone number, including area code) | |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act). Yes
 No

At November 8, 2013, there were 500,006,833 shares of common stock outstanding.

Table of Contents

TABLE OF CONTENTS

| | Page |
|--|-----------|
| <u>PART I — FINANCIAL INFORMATION</u> | <u>1</u> |
| Item 1. <u>Financial Statements</u> | <u>1</u> |
| Condensed Consolidated and Combined Statements of Income (Unaudited) | <u>1</u> |
| Condensed Consolidated and Combined Statements of Comprehensive Income (Unaudited) | <u>2</u> |
| Condensed Consolidated (Unaudited) and Combined Balance Sheets | <u>3</u> |
| Condensed Consolidated and Combined Statements of Equity (Unaudited) | <u>4</u> |
| Condensed Consolidated and Combined Statements of Cash Flows (Unaudited) | <u>5</u> |
| Notes to Condensed Consolidated and Combined Financial Statements (Unaudited) | <u>6</u> |
| Review Report of Independent Registered Public Accounting Firm | <u>27</u> |
| Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u> | <u>28</u> |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u> | <u>52</u> |
| Item 4. <u>Controls and Procedures</u> | <u>53</u> |
| <u>PART II — OTHER INFORMATION</u> | <u>54</u> |
| Item 1. <u>Legal Proceedings</u> | <u>54</u> |
| Item 1A. <u>Risk Factors</u> | <u>54</u> |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>58</u> |
| Item 3. <u>Defaults Upon Senior Securities</u> | <u>58</u> |
| Item 4. <u>Mine Safety Disclosures</u> | <u>58</u> |
| Item 5. <u>Other Information</u> | <u>58</u> |
| Item 6. <u>Exhibits</u> | <u>59</u> |
| <u>SIGNATURES</u> | <u>60</u> |

Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ZOETIS INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME

(UNAUDITED)

| | Three Months Ended | | Nine Months Ended | |
|--|--------------------|-----------|-------------------|-----------|
| | September | September | September | September |
| | 29, | 30, | 29, | 30, |
| (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) | 2013 | 2012 | 2013 | 2012 |
| Revenue | \$1,103 | \$1,019 | \$3,307 | \$3,160 |
| Costs and expenses: | | | | |
| Cost of sales ^(a) | 385 | 359 | 1,203 | 1,130 |
| Selling, general and administrative expenses ^(a) | 399 | 335 | 1,155 | 1,017 |
| Research and development expenses ^(a) | 93 | 94 | 278 | 288 |
| Amortization of intangible assets ^(a) | 15 | 16 | 45 | 48 |
| Restructuring charges and certain acquisition-related costs | 3 | 6 | (10 |) 55 |
| Interest expense, net of capitalized interest | 29 | 7 | 83 | 23 |
| Other (income)/deductions—net | (6 |) (11 |) (11 |) (37 |
| Income before provision for taxes on income | 185 | 213 | 564 | 636 |
| Provision for taxes on income | 54 | 52 | 165 | 190 |
| Net income before allocation to noncontrolling interests | 131 | 161 | 399 | 446 |
| Less: Net income/(loss) attributable to noncontrolling interests | — | (1 |) — | — |
| Net income attributable to Zoetis Inc. | \$131 | \$162 | \$399 | \$446 |
| Earnings per share attributable to Zoetis Inc. stockholders: | | | | |
| Basic | \$0.26 | \$0.32 | \$0.80 | \$0.89 |
| Diluted | \$0.26 | \$0.32 | \$0.80 | \$0.89 |
| Weighted-average common shares outstanding: | | | | |
| Basic | 500.000 | 500.000 | 500.000 | 500.000 |
| Diluted | 500.354 | 500.000 | 500.227 | 500.000 |
| Dividends declared per common share | \$0.065 | \$— | \$0.195 | \$— |

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate, in the condensed consolidated and combined statements of income.

See notes to condensed consolidated and combined financial statements.

Table of Contents

ZOETIS INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME
 (UNAUDITED)

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | | | |
| Net income before allocation to noncontrolling interests | \$131 | \$161 | \$399 | \$446 |
| Other comprehensive income/(loss), net of taxes and reclassification adjustments ^(a) : | | | | |
| Foreign currency translation adjustments, net | (62 |) 22 | (79 |) (106 |
| Benefit plans: Actuarial gains/(losses), net | — | 2 | (3 |) 2 |
| Total other comprehensive income/(loss), net of tax | (62 |) 24 | (82 |) (104 |
| Comprehensive income before allocation to noncontrolling interests | 69 | 185 | 317 | 342 |
| Less: Comprehensive income/(loss) attributable to noncontrolling interests | — | (1 |) — | — |
| Comprehensive income attributable to Zoetis Inc. | \$69 | \$186 | \$317 | \$342 |

Presented net of reclassification adjustments and tax impacts, which are not significant in any period presented.

^(a) Reclassification adjustments related to benefit plans are generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, general and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated and combined statements of income.

See notes to condensed consolidated and combined financial statements.

2 |

Table of Contents

ZOETIS INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS

| (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) | September 29, 2013 ^(a) | December 31, 2012 ^(a) |
|---|--------------------------------------|-------------------------------------|
| | (Unaudited) | |
| Assets | | |
| Cash and cash equivalents | \$389 | \$317 |
| Accounts receivable, less allowance for doubtful accounts of \$36 in 2013 and \$49 in 2012 | 1,110 | 900 |
| Inventories | 1,290 | 1,345 |
| Current deferred tax assets | 66 | 101 |
| Other current assets | 228 | 201 |
| Total current assets | 3,083 | 2,864 |
| Property, plant and equipment, less accumulated depreciation of \$996 in 2013 and \$1,011 in 2012 | 1,252 | 1,241 |
| Goodwill | 980 | 985 |
| Identifiable intangible assets, less accumulated amortization | 815 | 868 |
| Noncurrent deferred tax assets | 70 | 216 |
| Other noncurrent assets | 59 | 88 |
| Total assets | \$6,259 | \$6,262 |
| Liabilities and Equity | | |
| Short-term borrowings, including current portion of allocated long-term debt in 2012 | \$10 | \$73 |
| Accounts payable | 482 | 319 |
| Accrued compensation and related items | 184 | 194 |
| Income taxes payable | 121 | 30 |
| Dividends payable | 33 | — |
| Other current liabilities | 478 | 507 |
| Total current liabilities | 1,308 | 1,123 |
| Long-term debt | 3,642 | — |
| Allocated long-term debt | — | 509 |
| Noncurrent deferred tax liabilities | 269 | 323 |
| Other taxes payable | 41 | 159 |
| Other noncurrent liabilities | 133 | 107 |
| Total liabilities | 5,393 | 2,221 |
| Commitments and contingencies | | |
| Business unit equity | — | 4,183 |
| Stockholders' equity: | | |
| Common stock, \$0.01 par value: 5,000 authorized, 500 issued and outstanding | 5 | — |
| Additional paid-in capital | 876 | — |
| Retained earnings | 207 | — |
| Accumulated other comprehensive loss | (245 |) (157 |
| Total Zoetis Inc. equity | 843 | 4,026 |
| Equity attributable to noncontrolling interests | 23 | 15 |
| Total equity | 866 | 4,041 |
| Total liabilities and equity | \$6,259 | \$6,262 |

^(a) The condensed consolidated balance sheet as of September 29, 2013 has been prepared under a different basis of presentation than the condensed combined

balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

See notes to condensed consolidated and combined financial statements.

3 |

Table of Contents

ZOETIS INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY
 (UNAUDITED)

| | Zoetis | | | | | Accumulated Other Comprehensive Loss | Equity Attributable to Noncontrolling Interests | Total Equity | |
|---|---|--------------------------------|--------------------|----------------------|---------|---|---|-----------------|---|
| | Business Unit Equity ^(a) | Common Stock ^(b) | Paid-in Capital | Retained Earnings | | | | | |
| (MILLIONS OF DOLLARS) | | | | | | | | | |
| Balance, December 31, 2011 | \$3,785 | \$— | \$— | \$— | \$ (65 |) | \$ 16 | \$3,736 | |
| Nine months ended September 30, 2012 | | | | | | | | | |
| Comprehensive income | 446 | — | — | — | (104 |) | — | 342 | |
| Share-based compensation expense | 18 | — | — | — | — | | — | 18 | |
| Dividends declared and paid | (63 |) | — | — | — | | — | (63 |) |
| Net transfers between Pfizer Inc. and noncontrolling interests | 1 | — | — | — | — | | (1 |) | — |
| Net transfers—Pfizer Inc. | 76 | — | — | — | — | | — | 76 | |
| Balance, September 30, 2012 | \$4,263 | \$— | \$— | \$— | \$ (169 |) | \$ 15 | \$4,109 | |
| Balance, December 31, 2012 | \$4,183 | \$— | \$— | \$— | \$ (157 |) | \$ 15 | \$4,041 | |
| Nine months ended September 29, 2013 | | | | | | | | | |
| Comprehensive income | 94 | — | — | 305 | (82 |) | — | 317 | |
| Share-based compensation expense | 3 | — | 34 | — | — | | — | 37 | |
| Net transfers—Pfizer Inc. | (271 |) | — | — | — | | — | (271 |) |
| Separation adjustments ^(c) | 414 | — | 34 | — | (6 |) | 8 | 450 | |
| Employee benefit plan contribution from Pfizer Inc. ^(d) | — | — | 1 | — | — | | — | 1 | |
| Reclassification of net liability due to Pfizer Inc. ^(e) | (60 |) | — | — | — | | — | (60 |) |
| Consideration paid to Pfizer Inc. in connection with the Separation ^(f) | — | — | (3,551 |) | — | | — | (3,551 |) |
| Issuance of common stock to Pfizer Inc. in connection with the Separation and reclassification of Business Unit Equity ^(f) | (4,363 |) | 5 | 4,358 | — | | — | — | |
| Dividends declared | — | — | — | (98 |) | | — | (98 |) |
| Balance, September 29, 2013 | \$— | \$5 | \$ 876 | \$207 | \$ (245 |) | \$ 23 | \$866 | |

All amounts associated with Business Unit Equity relate to periods prior to the Separation. See Note 2A. The

^(a) Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

Edgar Filing: Zoetis Inc. - Form 10-Q

- (b) As of September 29, 2013, there were 500,006,833 outstanding shares of common stock.
- (c) For additional information, see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
- (d) Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 12. Benefit Plans. Represents the reclassification of the Receivable from Pfizer Inc. and the Payable to Pfizer Inc. from Business Unit
- (e) Equity as of the Separation date. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
- (f) Reflects the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

See notes to condensed consolidated and combined financial statements.

4 |

Table of Contents

ZOETIS INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS
 (UNAUDITED)

| | Nine Months Ended | |
|---|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | |
| Operating Activities | | |
| Net income before allocation to noncontrolling interests | \$399 | \$446 |
| Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities: | | |
| Depreciation and amortization expense | 151 | 156 |
| Share-based compensation expense | 37 | 18 |
| Asset write-offs and asset impairments | 4 | 9 |
| Deferred taxes | (47) | (81) |
| Employee benefit plan contribution from Pfizer Inc. | 1 | — |
| Other non-cash adjustments | — | (2) |
| Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc. | (162) | (402) |
| Net cash provided by operating activities | 383 | 144 |
| Investing Activities | | |
| Purchases of property, plant and equipment | (135) | (81) |
| Net proceeds from sales of assets | 7 | — |
| Other investing activities | — | (8) |
| Net cash used in investing activities | (128) | (89) |
| Financing Activities | | |
| Increase in short-term borrowings, net | 11 | — |
| Proceeds from issuance of long-term debt—senior notes, net of discount and fees | 2,625 | — |
| Consideration paid to Pfizer Inc. in connection with the Separation ^(a) | (2,559) | — |
| Cash dividends paid ^(b) | (65) | (63) |
| Other net financing activities with Pfizer Inc. | (184) | 63 |
| Net cash (used in)/provided by financing activities | (172) | — |
| Effect of exchange-rate changes on cash and cash equivalents | (11) | (1) |
| Net increase in cash and cash equivalents | 72 | 54 |
| Cash and cash equivalents at beginning of period | 317 | 79 |
| Cash and cash equivalents at end of period | \$389 | \$133 |
| Supplemental cash flow information | | |
| Cash paid during the period for: | | |
| Income taxes | \$77 | \$276 |
| Interest, net of capitalized interest | 60 | 31 |
| Non-cash transactions: | | |
| Dividends declared, not paid | \$33 | \$— |
| Zoetis Inc. senior notes transferred to Pfizer Inc. in connection with the Separation ^(c) | 992 | — |

Reflects the Separation transaction. Amount is net of the non-cash portion. See Note 2A. The Separation,

^(a) Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

^(b) Payments to other non-Zoetis Pfizer Inc. entities for the nine months ended September 30, 2012.

- (c) Reflects the non-cash portion of the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

See notes to condensed consolidated and combined financial statements.

5 |

Table of Contents

ZOETIS INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED AND COMBINED FINANCIAL STATEMENTS
(UNAUDITED)

1. Organization

Zoetis Inc. (collectively, Zoetis, the company, we, us or our) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. We organize and operate our business in four geographic regions: the United States (U.S.); Europe/Africa/Middle East (EuAfME); Canada/Latin America (CLAR); and Asia/Pacific (APAC). We market our products in more than 120 countries, including developed markets and emerging markets. Our revenue is mostly generated in the U.S. and EuAfME. We have a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

2. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer

Pfizer Inc. (Pfizer) formed Zoetis to acquire, own and operate the animal health business of Pfizer. On June 24, 2013, Pfizer completed an exchange offer resulting in the full separation of Zoetis from Pfizer. For additional information, see E. Exchange Offer.

A. The Separation

In the first quarter of 2013, through a series of steps (collectively, the Separation), Pfizer transferred to us its subsidiaries holding substantially all of the assets and liabilities of its animal health business. In exchange, we transferred to Pfizer: (i) all of the issued and outstanding shares of our Class A common stock; (ii) all of the issued and outstanding shares of our Class B common stock; (iii) \$1.0 billion in senior notes (see C. Senior Notes Offering below); and (iv) an amount of cash equal to substantially all of the net proceeds received in the senior notes offering (approximately \$2.5 billion).

B. Adjustments Associated with the Separation

In connection with the Separation, certain animal health assets and liabilities included in the pre-Separation balance sheet were retained by Pfizer and certain non-animal health assets and liabilities (not included in the pre-Separation balance sheet) were transferred to Zoetis. The adjustments to the historical balance sheet of Zoetis (collectively, the Separation Adjustments) representing approximately \$450 million of net liabilities retained by Pfizer, were primarily related to the following:

The removal of inventories (approximately \$74 million), property, plant and equipment (approximately \$28 million) and miscellaneous other net liabilities (approximately \$21 million) associated with certain non-dedicated manufacturing sites that were retained by Pfizer;

The addition of property, plant and equipment (approximately \$56 million) associated with a non-dedicated manufacturing site that was transferred to us by Pfizer (and then leased back to Pfizer under operating leases), and the removal of the inventory (approximately \$46 million) and net other assets (approximately \$4 million) at that site as these assets were retained by Pfizer;

The addition of net benefit plan liabilities (approximately \$25 million);

The elimination of (i) noncurrent deferred tax assets (some of which were included within noncurrent deferred tax liabilities due to jurisdictional netting) related to net operating loss and tax credit carryforwards; (ii) net tax liabilities associated with uncertain tax positions; (iii) noncurrent deferred tax liabilities related to deferred income taxes on unremitted earnings; and (iv) other allocated net tax assets, all of which (approximately \$49 million in net tax asset accounts) were retained by Pfizer;

The addition of (i) noncurrent deferred tax assets (approximately \$8 million, some of which were included within noncurrent deferred tax liabilities due to jurisdictional netting) related to net benefit plan liabilities transferred to us by Pfizer; (ii) noncurrent deferred tax assets (approximately \$2 million) related to net operating loss and tax credit carryforwards; and (iii) noncurrent deferred tax liabilities (approximately \$2 million) related to property, plant and equipment transferred to us by Pfizer;

The elimination of allocated long-term debt (approximately \$582 million), allocated accrued interest payable (approximately \$16 million) and allocated unamortized deferred debt issuance costs (approximately \$2 million) that were retained by Pfizer;

Certain net financial assets retained by Pfizer (approximately \$45 million);

The removal of cash (approximately \$7 million), inventories (approximately \$5 million), property, plant and equipment (approximately \$8 million), miscellaneous other assets (approximately \$3 million) and other miscellaneous liabilities (approximately \$2 million) associated with non-U.S. Pfizer businesses that did not transfer to us from Pfizer;

The addition of net receivables from Pfizer (approximately \$5 million) associated with certain foreign taxes directly resulting from certain aspects of the Separation that were the responsibility of Pfizer under the terms of the tax matters agreement, see Note 7B. Income Taxes: Tax Matters Agreement;

Table of Contents

The addition of (i) inventory (approximately \$15 million); (ii) net deferred tax assets (approximately \$1 million); and (iii) miscellaneous other assets (approximately \$5 million) transferred to us by Pfizer, and the removal of (i) property, plant and equipment (approximately \$2 million); (ii) miscellaneous other liabilities (approximately \$57 million), and (iii) the elimination of prepaid taxes (approximately \$4 million) that were retained by Pfizer; and

- The addition of net benefit plan liabilities (approximately \$16 million) associated with certain international plans that will be transferred from Pfizer to Zoetis in 2014. See Note 12. Benefit Plans.

The Separation Adjustment associated with Accumulated Other Comprehensive Income reflects the accumulated currency translation adjustment based on the actual legal entity structure of Zoetis.

C. Senior Notes Offering

In connection with the Separation, on January 28, 2013, we issued \$3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of \$10 million. For additional information, see Note 9D. Financial Instruments: Senior Notes Offering.

D. Initial Public Offering (IPO)

After the Separation, on February 6, 2013, an IPO of 99,015,000 shares of our Class A common stock (including the exercise of the underwriters' over-allotment option) at a price of \$26.00 per share was completed. Pfizer retained the net proceeds from the IPO.

Immediately following the IPO, there were 99,015,000 outstanding shares of Class A common stock and 400,985,000 outstanding shares of Class B common stock. The rights of the holders of Class A common stock and Class B common stock are identical, except with respect to voting and conversion rights. Following the IPO, Pfizer owned all of the outstanding shares of our Class B common stock, all of which was converted to Class A common stock in connection with the Exchange Offer. See E. Exchange Offer. There are no longer any shares of our Class B common stock outstanding.

In connection with the IPO, we entered into certain agreements that provide a framework for an ongoing relationship with Pfizer. For additional information, see Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.

E. Exchange Offer

On May 22, 2013, Pfizer announced an exchange offer (the Exchange Offer) whereby Pfizer shareholders could exchange a portion of Pfizer common stock for Zoetis common stock. The Exchange Offer was completed on June 24, 2013, resulting in the full separation of Zoetis and the disposal of Pfizer's entire ownership and voting interest in Zoetis.

3. Basis of Presentation

The accompanying unaudited condensed consolidated and combined financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine-month periods ended August 25, 2013 and August 26, 2012.

Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited condensed consolidated and combined financial statements included in this Form 10-Q. The condensed consolidated and combined financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the combined financial statements and accompanying notes included in the Company's 2012 Annual Report on Form 10-K.

A. Basis of Presentation Prior to the Separation

Prior to the Separation, the combined financial statements were derived from the consolidated financial statements and accounting records of Pfizer and included allocations for direct costs and indirect costs attributable to the operations of the animal health business of Pfizer. The pre-Separation financial statements and activities do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been

had we operated as a standalone public company during the period presented.

The condensed combined statements of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include allocations from certain support functions (Enabling Functions) that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, and, to a lesser extent, business development, public affairs and procurement, among others, as Pfizer does not routinely allocate these costs to any of its business units. These allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods (e.g., using third-party sales, headcount, etc.), depending on the nature of the services.

Costs associated with business technology, facilities and human resources were allocated primarily using proportional allocation methods and, for legal and finance, primarily using specific identification. In all cases, for support function costs where proportional allocation methods were used, we determined whether the costs are primarily influenced by headcount (such as a significant majority

Table of Contents

of facilities and human resources costs) or by the size of the business (such as most business technology costs), and we also determined whether the associated scope of those services provided are global, regional or local. Based on those analyses, the costs were allocated based on our share of worldwide revenue, domestic revenue, international revenue, regional revenue, country revenue, worldwide headcount, country headcount or site headcount, as appropriate.

As a result, costs associated with business technology and legal that were not specifically identified were mostly allocated based on revenue drivers and, to a lesser extent, based on headcount drivers; costs associated with finance that were not specifically identified were all allocated based on revenue drivers; and costs associated with facilities and human resources that were not specifically identified were predominantly allocated based on headcount drivers. The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include allocations of certain manufacturing and supply costs incurred by manufacturing plants that are shared with other Pfizer business units, Pfizer's global external supply group and Pfizer's global logistics and support group (collectively, Pfizer Global Supply, or PGS). These costs may include manufacturing variances and changes in the standard costs of inventory, among others, as Pfizer does not routinely allocate these costs to any of its business units. These allocations are based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods, such as animal health identified manufacturing costs, depending on the nature of the costs.

The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 also include allocations from the Enabling Functions and PGS for restructuring charges, integration costs, additional depreciation associated with asset restructuring and implementation costs, as Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives. The condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013 include an allocation of share-based compensation expense and certain other compensation expense items, such as certain fringe benefit expenses, maintained on a centralized basis within Pfizer, as Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of share-based payments, see Note 13. Share-Based Payments.

The condensed combined balance sheet as of December 31, 2012 reflects all of the assets and liabilities of Pfizer that are either specifically identifiable or are directly attributable to Zoetis and its operations. For benefit plans, the combined balance sheet only includes the assets and liabilities of benefit plans dedicated to animal health employees. For debt, see below.

The condensed combined balance sheet as of December 31, 2012 includes an allocation of long-term debt from Pfizer that was issued to partially finance the acquisition of Wyeth (including Fort Dodge Animal Health (FDAH)). The debt and associated interest-related expenses, including the effect of hedging activities, have been allocated on a pro-rata basis using the deemed acquisition cost of FDAH as a percentage of the total acquisition cost of Wyeth. No other allocations of debt have been made as none are specifically related to our operations.

The allocated expenses from Pfizer include the items noted below for the pre-Separation period in 2013 and the three and nine months ended September 30, 2012.

Enabling Functions operating expenses—\$11 million in 2013 and \$77 million and \$229 million in the three and nine months ended September 30, 2012, respectively (\$1 million in the nine months ended September 30, 2012 in Cost of sales; \$11 million in 2013 and \$62 million and \$185 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and \$15 million and \$43 million in the three and nine months ended September 30, 2012, respectively, in Research and development expenses).

PGS manufacturing costs—approximately \$2 million and \$14 million in the three and nine months ended September 30, 2012, respectively (in Cost of sales).

Restructuring charges and certain acquisition-related costs—\$12 million and \$47 million in the three and nine months ended September 30, 2012, respectively (in Restructuring charges and certain acquisition-related costs).

Other costs associated with cost reduction/productivity initiatives—additional depreciation associated with asset restructuring—\$2 million in 2013 (in Selling, general and administrative expenses) and \$1 million and \$10 million in the three and nine months ended September 30, 2012, respectively (in Research and development expenses).

Other costs associated with cost reduction/productivity initiatives—implementation costs—\$1 million in 2013 and \$2 million and \$4 million in the three and nine months ended September 30, 2012, respectively (in Selling, general and administrative expenses).

Share-based compensation expense—approximately \$3 million in 2013 and \$6 million and \$22 million in the three and nine months ended September 30, 2012, respectively (\$1 million in 2013 and \$3 million and \$5 million in the three and nine months ended September 30, 2012, respectively, in Cost of sales; \$2 million in 2013 and \$3 million and \$14 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and \$3 million in the nine months ended September 30, 2012 in Research and development expenses).

Table of Contents

Compensation-related expenses—approximately \$1 million in 2013 and \$5 million and \$16 million in the three and nine months ended September 30, 2012, respectively (\$2 million and \$5 million in the three and nine months ended September 30, 2012, respectively, in Cost of sales; \$1 million in 2013 and \$2 million and \$7 million in the three and nine months ended September 30, 2012, respectively, in Selling, general and administrative expenses; and \$1 million and \$4 million in the three and nine months ended September 30, 2012, respectively, in Research and development expenses).

Interest expense—approximately \$2 million in 2013 and \$7 million and \$23 million in the three and nine months ended September 30, 2012, respectively.

The income tax provision in the condensed combined statement of income was calculated as if Zoetis filed a separate return.

Management believes that the allocations are a reasonable reflection of the services received or the costs incurred on behalf of Zoetis and its operations and that the condensed combined statement of income for the three and nine months ended September 30, 2012 and the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013.

Prior to the Separation, we participated in Pfizer's centralized cash management system and generally all excess cash was transferred to Pfizer on a daily basis. Cash disbursements for operations and/or investing activities were funded as needed by Pfizer. We had also participated in Pfizer's centralized hedging and offsetting programs. As such, in the combined statement of income for the three and nine months ended September 30, 2012, we include the impact of Pfizer's derivative financial instruments used for offsetting changes in foreign currency rates, net of the related foreign exchange gains and losses for the portion that is deemed to be associated with the animal health operations. Such gains and losses were not material to the combined financial statement for the periods presented.

As of December 31, 2012, all balances and transactions among Zoetis and Pfizer and its subsidiaries, which can include dividends as well as other activities, are shown in Business unit equity in the combined balance sheet. As the books and records of Zoetis were not kept on a separate company basis, the determination of the average net balance due to or from Pfizer is not practicable.

B. Basis of Presentation After the Separation

The unaudited condensed consolidated financial statements as of and for the three and nine months ended September 29, 2013 comprise the following: (i) the results of operations, comprehensive income, and cash flow amounts for the period prior to the Separation (see above), which includes allocations for direct costs and indirect costs attributable to the operations of the animal health business; and (ii) the amounts for the period after the Separation, which reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operation as a standalone public company.

The income tax provision prepared after the Separation is based on the actual legal entity structure of Zoetis, with certain accommodations pursuant to a tax matters agreement. For additional information, see Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.

4. Significant Accounting Policies

A. New Accounting Standards

There were no new accounting standards adopted during the first nine months of 2013.

B. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incurred significant costs in connection with Pfizer's cost-reduction initiatives (several programs initiated since 2005), and the acquisitions of Fort Dodge Animal Health (FDAH) on October 15, 2009 and King Animal Health

(KAH) on January 31, 2011.

For example:

in connection with the cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and

9 |

Table of Contents

in connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company.

All operating functions can be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as functions such as business technology, shared services and corporate operations.

The components of costs incurred in connection with our acquisitions and restructuring initiatives follow:

| (MILLIONS OF DOLLARS) | Three Months Ended | | Nine Months Ended | |
|--|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| Restructuring charges and certain acquisition-related costs: | | | | |
| Integration costs ^(a) | \$3 | \$6 | \$16 | \$15 |
| Restructuring charges (benefits) ^(b) : | | | | |
| Employee termination costs | — | (13) | (26) | (10) |
| Asset impairment charges | — | 1 | — | 2 |
| Exit costs | — | — | — | 1 |
| Total direct | 3 | (6) | (10) | 8 |
| Integration costs ^(a) | — | 4 | — | 16 |
| Restructuring charges ^(b) : | | | | |
| Employee termination costs | — | 5 | — | 19 |
| Asset impairment charges | — | — | — | 8 |
| Exit costs | — | 3 | — | 4 |
| Total allocated | — | 12 | — | 47 |
| Total Restructuring charges and certain acquisition-related costs | 3 | 6 | (10) | 55 |
| Other costs associated with cost-reduction/productivity initiatives: | | | | |
| Additional depreciation associated with asset restructuring—direct | — | 5 | 1 | 10 |
| Additional depreciation associated with asset restructuring—allocated | — | 1 | 2 | 10 |
| Implementation costs—allocated | — | 2 | 1 | 4 |
| Total costs associated with acquisitions and cost-reduction/productivity initiatives | \$3 | \$14 | \$(6) | \$79 |

(a) Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes.

The restructuring benefit for the nine months ended September 29, 2013 is related to the reversal of certain employee termination expenses associated with our operations in Europe. In the fourth quarter of 2012, when we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of \$27 million to recognize employee termination costs. As a

(b) result of becoming a standalone public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of \$27 million in the second quarter of 2013. The restructuring benefits for the three and nine months ended September 30, 2012 are primarily related to the sale of a manufacturing plant.

The direct restructuring charges (benefits) are associated with the following:

For the nine months ended September 29, 2013—Manufacturing/research/corporate (\$26 million income).

For the three months ended September 30, 2012—EuAfME (\$3 million) and manufacturing/research/corporate (\$15 million income).

For the nine months ended September 30, 2012—U.S. (\$3 million), EuAfME (\$2 million), CLAR (\$1 million), and manufacturing/research/corporate (\$13 million income, resulting from the sale of a manufacturing plant).

Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of sales (\$1 million) and Selling, general and administrative expenses (\$2 million). For the three months ended (c) September 30, 2012, included in Cost of sales (\$4 million), Selling, general and administrative expenses (\$1 million) and Research and development expenses (\$1 million). For the nine months ended September 30, 2012, included in Cost of sales (\$9 million), Selling, general and administrative expenses (\$1 million) and Research and development expenses (\$10 million).

Implementation costs—allocated represent external, incremental costs directly related to implementing cost (d) reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.

Table of Contents

The components of and changes in our direct restructuring accruals follow:

| (MILLIONS OF DOLLARS) | Employee Termination Costs | Asset Impairment Charges | Exit Costs | Accrual |
|--|----------------------------------|--------------------------------|---------------|---------|
| Balance, December 31, 2012 ^(a) | \$ 68 | \$— | \$6 | \$74 |
| Provision/(Benefit) | (26) | — | — | (26) |
| Utilization and other ^(b) | (13) | — | (4) | (17) |
| Separation adjustment ^(c) | (14) | — | — | (14) |
| Balance, September 29, 2013 ^(a) | \$ 15 | \$— | \$2 | \$17 |

(a) At September 29, 2013 and December 31, 2012, included in Other current liabilities (\$8 million and \$63 million, respectively) and Other noncurrent liabilities (\$9 million and \$11 million, respectively).

(b) Includes adjustments for foreign currency translation.

(c) See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

6. Other (Income)/Deductions—Net

The components of Other (income)/deductions—net follow:

| (MILLIONS OF DOLLARS) | Three Months Ended | | Nine Months Ended | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| Royalty-related income | \$(8) | \$(11) | \$(21) | \$(24) |
| Identifiable intangible asset impairment charges ^(a) | — | 2 | 1 | 5 |
| Net gain on sale of assets ^(b) | — | — | (6) | — |
| Certain legal matters, net ^(c) | 1 | — | 1 | (19) |
| Foreign currency (gain)/loss ^(d) | — | (1) | 12 | 2 |
| Other, net | 1 | (1) | 2 | (1) |
| Other (income)/deductions—net | \$(6) | \$(11) | \$(11) | \$(37) |

For the nine months ended September 30, 2012, the intangible asset impairment charges include (i) approximately \$2 million of finite-lived companion animal developed technology rights; (ii) approximately \$1 million of finite-lived trademarks related to genetic testing services; and (iii) approximately \$2 million of finite-lived patents related to poultry technology. These intangible asset impairment charges reflect, among other things, loss of revenue as a result of negative market conditions and, with respect to the poultry technology, a re-assessment of economic viability.

(b) For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.

(c) For the nine months ended September 30, 2012, represents income from a favorable legal settlement related to an intellectual property matter (\$14 million) and a change in estimate for an environmental-related reserve due to a favorable settlement (\$7 million income) partially offset by litigation-related charges (\$2 million).

(d) For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.

7. Income Taxes

A. Taxes on Income

The effective tax rate was 29.2% for the third quarter of 2013, compared to 24.4% for the third quarter of 2012. The higher effective tax rate in the third quarter of 2013 compared to the third quarter of 2012 was primarily attributable to:

• a \$29 million tax benefit during the third quarter of 2012 resulting from Pfizer's settlement with the U.S. Internal Revenue Service (IRS) with respect to the audits of the Pfizer Inc. tax returns for the years 2006 through 2008; partially offset by:

• incentive tax rulings in Belgium, effective December 31, 2012, and Singapore, effective October 29, 2012; and

changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs.

The effective tax rate was 29.3% for the first nine months of 2013, compared to 29.9% for the first nine months of 2012. The lower effective tax rate in the first nine months of 2013 compared to the first nine months of 2012 was primarily attributable to:

- the aforementioned incentive tax rulings and changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs; and

- a \$2 million discrete income tax benefit during the first quarter of 2013 related to the 2012 U.S. research and development tax credit which was retroactively extended on January 3, 2013; partially offset by:

Table of Contents

the tax benefit resulting from the aforementioned \$29 million IRS settlement in 2012.

As of the Separation date, we operate under a new standalone legal entity structure. In connection with the Separation, adjustments have been made to the income tax accounts. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

B. Tax Matters Agreement

In connection with the Separation, we entered into a tax matters agreement with Pfizer that governs the parties' respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. For additional information, see below and Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.

In connection with this agreement and the Separation, the activity in our income tax accounts reflects Separation Adjustments, including significant adjustments to the deferred income tax asset and liability accounts and the tax liabilities associated with uncertain tax positions. For additional information, see below and Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

In general, under the agreement:

Pfizer will be responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments and including those taxes attributable to our business) reportable on a consolidated, combined or unitary return that includes Pfizer or any of its subsidiaries (and us and/or any of our subsidiaries) for any periods or portions thereof ending on or prior to December 31, 2012. We will be responsible for the portion of any such taxes for periods or portions thereof beginning on or after January 1, 2013, as would be applicable to us if we filed the relevant tax returns on a standalone basis.

We will be responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments) that are reportable on returns that include only us and/or any of our subsidiaries, for all tax periods whether before or after the completion of the Separation.

Pfizer will be responsible for certain specified foreign taxes directly resulting from certain aspects of the Separation. We will not generally be entitled to receive payment from Pfizer in respect of any of our tax attributes or tax benefits or any reduction of taxes of Pfizer. Neither party's obligations under the agreement will be limited in amount or subject to any cap. The agreement also assigns responsibilities for administrative matters, such as the filing of returns, payment of taxes due, retention of records and conduct of audits, examinations or similar proceedings. In addition, the agreement provides for cooperation and information sharing with respect to tax matters.

Pfizer will be primarily responsible for preparing and filing any tax return with respect to the Pfizer affiliated group for U.S. federal income tax purposes and with respect to any consolidated, combined, unitary or similar group for U.S. state or local or foreign income tax purposes or U.S. state or local non-income tax purposes that includes Pfizer or any of its subsidiaries, including those that also include us and/or any of our subsidiaries. We will generally be responsible for preparing and filing any tax returns that include only us and/or any of our subsidiaries.

The party responsible for preparing and filing a given tax return will generally have exclusive authority to control tax contests related to any such tax return.

C. Deferred Taxes

As of September 29, 2013, the total net deferred income tax liability of \$137 million is included in Current deferred tax assets (\$66 million), Noncurrent deferred tax assets (\$70 million), Other current liabilities (\$4 million) and Noncurrent deferred tax liabilities (\$269 million).

As of December 31, 2012, the total net deferred income tax liability of \$8 million is included in Current deferred tax assets (\$101 million), Noncurrent deferred tax assets (\$216 million), Other current liabilities (\$2 million) and Noncurrent deferred tax liabilities (\$323 million).

The significant increase in the total net deferred tax liability from December 31, 2012 to September 29, 2013 is primarily attributable to the Separation Adjustments, predominantly related to deferred tax assets associated with net operating loss/credit carry forwards and deferred tax liabilities associated with unremitted earnings that were retained

by Pfizer. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

D. Tax Contingencies

As of September 29, 2013, the tax liabilities associated with uncertain tax positions of \$38 million (exclusive of interest related to uncertain tax positions of \$10 million) were included in Noncurrent deferred tax assets (\$7 million) and Other taxes payable (\$31 million).

As of December 31, 2012, the tax liabilities associated with uncertain tax positions of \$144 million (exclusive of interest related to uncertain tax positions of \$17 million) were included in Noncurrent deferred tax assets (\$6 million) and Other taxes payable (\$138 million).

The significant decrease in the tax liabilities associated with uncertain tax positions from December 31, 2012 to September 29, 2013 is primarily attributable to the Separation Adjustments predominantly related to liabilities retained by Pfizer. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if

Table of Contents

recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

8. Accumulated Other Comprehensive Loss

Changes, net of tax, in accumulated other comprehensive loss follow:

| | Currency Translation Adjustment | Benefit Plans Actuarial Gains/(Losses) | Accumulated Other Comprehensive Loss |
|---------------------------------------|---------------------------------------|--|---|
| (MILLIONS OF DOLLARS) | | | |
| Balance, December 31, 2012 | \$(152) |) \$(5) |) \$(157) |
| Other comprehensive loss, net of tax | (79) |) (3) |) (82) |
| Separation adjustments ^(a) | (7) |) 1 |) (6) |
| Balance, September 29, 2013 | \$(238) |) \$(7) |) \$(245) |

(a) See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

9. Financial Instruments

A. Credit Facilities

In December 2012, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year \$1.0 billion senior unsecured revolving credit facility (the credit facility), which became effective in February 2013 upon the completion of the IPO and expires in December 2017. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 4.35:1 for fiscal year 2013, 3.95:1 for fiscal year 2014, 3.50:1 for fiscal year 2015 and 3.00:1 thereafter. The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants. Subject to certain conditions, we have the right to increase the credit facility to up to \$1.5 billion. There are currently no borrowings outstanding.

We have additional lines of credit with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 29, 2013, we had access to \$125 million of lines of credit which expire at various times through 2016. As of September 29, 2013, we had \$10 million of short-term borrowings outstanding and \$2 million of long-term borrowings outstanding related to these facilities.

B. Commercial Paper Program

In February 2013, we entered into a commercial paper program with a capacity of up to \$1.0 billion. As of September 29, 2013, no commercial paper has been issued under this program.

C. Short-Term Borrowings

There were short-term borrowings of \$10 million as of September 29, 2013 (see A. Credit Facilities). As of December 31, 2012 the current portion of allocated debt from Pfizer was \$73 million. The weighted-average interest rate on short-term borrowings outstanding, including the current portion of allocated debt, was 5.4% and 3.7% as of September 29, 2013 and December 31, 2012, respectively.

D. Senior Notes Offering and Other Long-Term Debt

On January 28, 2013, we issued \$3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of \$10 million. The senior notes are comprised of \$400 million aggregate principal amount of our 1.150% senior notes due 2016, \$750 million aggregate principal amount of our 1.875% senior notes due 2018, \$1.35 billion aggregate principal amount of our 3.250% senior notes due 2023 and \$1.15 billion aggregate principal amount of our 4.700% senior notes due 2043.

We sold \$2.65 billion aggregate principal amount of our senior notes through the initial purchasers in the senior notes offering and Pfizer transferred \$1.0 billion aggregate principal amount of our senior notes to certain of the initial purchasers, who sold such senior notes in the senior notes offering.

The senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell

Table of Contents

substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the senior notes, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2023 notes pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

In connection with the senior notes offering, we entered into a registration rights agreement (Registration Rights Agreement) with the representatives of the initial purchasers of the senior notes. Pursuant to the terms of the Registration Rights Agreement, we were obligated, among other things, to use our commercially reasonable efforts to file a registration statement with the SEC enabling holders of the senior notes to exchange the privately placed notes for publicly registered notes with substantially the same terms. We filed the registration statement with the SEC on September 13, 2013, the SEC declared the registration statement effective on September 24, 2013, and the exchange offer was completed on October 31, 2013.

The components of our long-term debt follow:

| (MILLIONS OF DOLLARS) | September 29, 2013 | December 31, 2012 |
|---|--------------------------|----------------------|
| Allocated long-term debt | \$— | \$509 |
| Lines of credit | 2 | — |
| 1.150% Senior Notes due 2016 | 400 | — |
| 1.875% Senior Notes due 2018 | 750 | — |
| 3.250% Senior Notes due 2023 | 1,350 | — |
| 4.700% Senior Notes due 2043 | 1,150 | — |
| | 3,652 | 509 |
| Unamortized debt discount | (10 |) — |
| Long-term debt / Allocated long-term debt | \$3,642 | \$509 |

As of September 29, 2013, the fair value of our long-term debt was \$3,502 million and has been determined using a third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and Zoetis's credit rating (Level 2 inputs). At December 31, 2012, the fair value of our allocated long-term debt was \$732 million, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and Pfizer's credit rating (Level 2 inputs). See Note 4B. Significant Accounting Policies: Fair Value. The fair value of the allocated long-term debt as of December 31, 2012 does not purport to reflect the fair value that might have been determined if Zoetis had operated as a standalone public company for the periods presented or if we had used Zoetis's credit rating in the calculation.

The principal amount of long-term debt outstanding as of September 29, 2013 matures in the following years:

| (MILLIONS OF DOLLARS) | 2014 | 2015 | 2016 | 2017 | 2018 | After 2018 | Total |
|-----------------------|------|------|-------|------|-------|---------------|---------|
| Maturities | \$— | \$— | \$401 | \$1 | \$750 | \$2,500 | \$3,652 |

E. Derivative Financial Instruments

Foreign Exchange Risk

A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. Prior to the IPO, as a business unit of Pfizer and under Pfizer's global cash management system, our foreign exchange risk was managed through Pfizer. Following the Separation, we seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market

conditions, foreign exchange risk is also managed through the use of derivative financial instruments. These financial instruments serve to protect net income against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. As of September 29, 2013, the aggregate notional amount of foreign exchange derivative financial instruments offsetting foreign currency exposures was \$1.5 billion. The derivative financial instruments primarily offset exposures in the euro, the Brazilian real and the Australian dollar. The vast majority of the foreign exchange derivative financial instruments mature within 60 days and all mature within 180 days. All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the condensed consolidated balance sheet. The company has not designated the foreign currency forward-exchange contracts as hedging instruments. We recognize the gains and losses on forward-exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.

Table of Contents

Fair Value of Derivative Instruments

The location and fair values of derivative instruments not designated as hedging instruments at September 29, 2013 are as follows:

| (MILLIONS OF DOLLARS) | Balance Sheet Location | Fair Value of Derivatives |
|---|---------------------------|---------------------------------|
| Foreign currency forward-exchange contracts | Other current assets | \$6 |
| Foreign currency forward-exchange contracts | Other current liabilities | (1) |
| Total foreign currency forward-exchange contracts | | \$5 |

We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value. See Note 4B. Significant Accounting Policies: Fair Value.

The net gains incurred on foreign currency forward-exchange contracts not designated as hedging instruments were \$13 million and \$32 million for the three and nine months ended September 29, 2013, respectively, and are recorded in Other (income)/deductions—net. These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

10. Inventories

The components of inventory follow:

| (MILLIONS OF DOLLARS) | September 29, 2013 | December 31, 2012 |
|----------------------------|-----------------------|----------------------|
| Finished goods | \$887 | \$799 |
| Work-in-process | 203 | 332 |
| Raw materials and supplies | 200 | 214 |
| Inventories | \$1,290 | \$1,345 |

11. Goodwill and Other Intangible Assets

A. Goodwill

The components of, and changes in, the carrying amount of goodwill follow:

| (MILLIONS OF DOLLARS) | U.S. | EuAfME | CLAR | APAC | Total |
|-----------------------------|-------|--------|-------|-------|-------|
| Balance, December 31, 2012 | \$502 | \$157 | \$163 | \$163 | \$985 |
| Other ^(a) | (2) | (1) | (1) | (1) | (5) |
| Balance, September 29, 2013 | \$500 | \$156 | \$162 | \$162 | \$980 |

^(a) Primarily reflects adjustments for foreign currency translation.

The gross goodwill balance was \$1,516 million as of September 29, 2013 and \$1,521 million as of December 31, 2012. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were \$536 million as of September 29, 2013 and December 31, 2012.

B. Other Intangible Assets

The components of identifiable intangible assets follow:

| (MILLIONS OF DOLLARS) | As of September 29, 2013 | | | As of December 31, 2012 | | |
|--|--------------------------|--------------|--|-------------------------|--------------|--|
| | Gross Carrying | Accumulated | Identifiable Intangible Assets, Less Accumulated | Gross Carrying | Accumulated | Identifiable Intangible Assets, Less Accumulated |
| | Amount | Amortization | Amortization | Amount | Amortization | Amortization |
| Finite-lived intangible assets: | | | | | | |
| Developed technology rights | \$761 | \$(207) | \$554 | \$762 | \$(173) | \$589 |
| Brands | 216 | (97) | 119 | 216 | (88) | 128 |
| Trademarks and trade names | 53 | (37) | 16 | 54 | (36) | 18 |
| Other | 122 | (116) | 6 | 122 | (115) | 7 |
| Total finite-lived intangible assets | 1,152 | (457) | 695 | 1,154 | (412) | 742 |
| Indefinite-lived intangible assets: | | | | | | |
| Brands | 39 | — | 39 | 39 | — | 39 |
| Trademarks and trade names | 67 | — | 67 | 67 | — | 67 |
| In-process research and development | 14 | — | 14 | 20 | — | 20 |
| Total indefinite-lived intangible assets | 120 | — | 120 | 126 | — | 126 |
| Identifiable intangible assets | \$1,272 | \$(457) | \$815 | \$1,280 | \$(412) | \$868 |

C. Amortization

Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was \$16 million for both the three months ended September 29, 2013 and September 30, 2012, and \$47 million and \$51 million for the nine months ended September 29, 2013 and September 30, 2012, respectively.

12. Benefit Plans

Prior to the Separation from Pfizer, employees who met certain eligibility requirements participated in various defined benefit pension plans and postretirement plans administered and sponsored by Pfizer. Effective December 31, 2012, our employees ceased to participate in the Pfizer U.S. qualified defined benefit and U.S. retiree medical plans, and liabilities associated with our employees under these plans were retained by Pfizer. Pfizer is continuing to credit certain employees' service with Zoetis generally through December 31, 2017 (or termination of employment from Zoetis, if earlier) for certain early retirement benefits with respect to Pfizer's U.S. defined benefit pension and retiree medical plans. In connection with the employee matters agreement, Zoetis will be responsible for payment of three-fifths of the total cost of the service credit continuation (approximately \$38 million) for these plans and Pfizer will fund the remaining two-fifths of the total cost (approximately \$25 million). The \$25 million capital contribution from Pfizer and corresponding contra-equity account (which will be reduced as the service credit continuation is incurred), is included in Employee benefit plan contribution from Pfizer Inc. in the Condensed Consolidated and

Combined Statements of Equity at September 29, 2013. The amount of the service cost continuation payment to be paid by Zoetis to Pfizer was determined and fixed based on an actuarial assessment of the value of the grow-in benefits and will be paid in equal installments over a period of ten years. Pension and postretirement benefit expense associated with the extended service for certain employees in the U.S. plans totaled approximately \$1 million and \$5 million for the three and nine months ended September 29, 2013, respectively.

Prior to the Separation from Pfizer, employees in the U.S. who met certain eligibility requirements participated in a supplemental (non-qualified) savings plan sponsored by Pfizer. In the second quarter of 2013, Pfizer transferred the supplemental savings plan liability of approximately \$14 million, cash of \$9 million and a deferred tax asset of \$5 million associated with employees transferred to us.

As part of the Separation, certain Separation Adjustments (see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation) were made to transfer the assets and liabilities of certain international defined benefit pension plans including Austria, France, Germany, Greece, Italy, Mexico, South Africa, Taiwan and Thailand, to Zoetis in the first quarter of 2013, and we assumed the liabilities allocable to employees transferring to us. Prior to the Separation, these benefit plans were accounted for as multi-employer plans. Also, as part of the Separation Adjustments, a benefit plan in Germany was retained by Pfizer. The net obligation of the transferred plans totaled \$25 million. At September 29, 2013, the projected benefit obligation and fair value of plan assets of the dedicated international pension plans in the Netherlands, Germany, India and Korea, as well as those plans transferred in the first quarter of 2013, were \$74 million and \$45 million, respectively. In the second quarter of 2013, a net liability of approximately \$16 million was recognized for the pension obligations less the fair value of plan assets associated with additional defined benefit pension plans in certain international locations that will be transferred to us in 2014, in accordance with the applicable local separation agreements.

Pension expense associated with dedicated international pension plans was approximately \$1 million and \$3 million for the three and nine months ended September 29, 2013, respectively. Pension expense associated with international benefit plans accounted for as multi-employer plans was approximately \$2 million and \$7 million for the three and nine months ended September 29, 2013, respectively.

Contributions to the dedicated international benefits plans for the three and nine months ended September 29, 2013 were \$1 million and \$2 million, respectively. Contributions to the international plans accounted for as multi-employer plans for the three and nine months ended September 29, 2013 were \$1 million and \$6 million, respectively. We expect to contribute a total of approximately \$9 million to these plans in 2013.

13. Share-Based Payments

A. Zoetis 2013 Equity and Incentive Plan

In January 2013, the Zoetis 2013 Equity and Incentive Plan (Equity Plan) became effective. The principal types of stock-based awards available under the Equity Plan may include, but are not limited to, the following:

Stock Options. Stock options represent the right to purchase shares of our common stock within a specified period of time at a specified price. The exercise price for a stock option will be not less than 100% of the fair market value of the common stock on the date of grant. Stock options will have a contractual maximum term of ten years from the date of grant. Stock options granted may include those intended to be “incentive stock options” within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986 (the Code).

Restricted Stock and Restricted Stock Units (RSUs). Restricted stock is a share of our common stock that is subject to a risk of forfeiture or other restrictions that will lapse subject to the recipient's continued employment, the attainment of performance goals, or both. Restricted stock units represent the right to receive shares of our common stock in the future (or cash determined by reference to the value of our common stock), subject to the recipient's continued employment, the attainment of performance goals, or both.

Deferred Stock Unit Awards (DSUs). Deferred stock unit awards, which are granted to non-employee Directors, represent the right to receive shares of our common stock at a future date. The DSU awards will be automatically settled and paid in shares (including fractional shares), within sixty days following the non-employee Director's separation of service on the Board of Directors.

Performance-Based Awards. Performance awards will require satisfaction of pre-established performance goals, consisting of one or more business criteria and a targeted performance level with respect to such criteria as a condition of awards vesting or being settled. Performance may be measured over a period of any length specified but not less than one year.

Other Equity-Based or Cash-Based Awards. Our Compensation Committee is authorized to grant awards in the form of other equity-based awards or other cash-based awards, as deemed to be consistent with the purposes of the Equity Plan. The maximum value of the aggregate payment to be paid to any participant with respect to cash-based awards under the Equity Plan in respect of an annual performance period will be \$10 million.

In order to provide long-term incentives to, and facilitate the retention of, our employees, we granted stock options (or other awards as appropriate with respect to our employees in non-U.S. jurisdictions) and/or restricted stock units under the Equity Plan on January 31, 2013 and February 1, 2013, respectively, to 1,700 of our employees. These awards will vest on the applicable three year anniversary date.

B. Share-Based Compensation Expense

The components of share-based compensation expense follow:

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | | | |
| Stock option expense | \$3 | \$— | \$7 | \$— |
| RSU / DSU expense | 3 | — | 5 | — |
| Pfizer stock benefit plans—direct | — | 6 | 25 | 18 |
| Share-based compensation expense—direct | 6 | 6 | 37 | 18 |
| Share-based compensation expense—indirect | — | — | — | 4 |
| Share-based compensation expense—total | \$6 | \$6 | \$37 | \$22 |

C. Stock Options

Stock options are accounted for using a fair-value-based method at the date of grant in the consolidated statement of income. The values determined through this fair-value-based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

Eligible employees may receive Zoetis stock option grants. Zoetis stock options granted vest after three years of continuous service from the grant date and have a contractual term of 10 years.

Table of Contents

The fair-value-based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions noted in the following table, shown at their weighted-average values:

| | Nine Months Ended September 29, 2013 | |
|--|---|---|
| Expected dividend yield ^(a) | 1.0 | % |
| Risk-free interest rate ^(b) | 1.30 | % |
| Expected stock price volatility ^(c) | 28.21 | % |
| Expected term ^(d) (years) | 6.5 | |

^(a) Determined using a constant dividend yield during the expected term of the Zoetis stock option.

^(b) Determined using the interpolated yield on U.S. Treasury zero-coupon issues.

^(c) Determined using implied volatility.

^(d) Determined using expected exercise and post-vesting termination patterns.

The following table provides an analysis of stock option activity for the nine months ended September 29, 2013:

| | Shares | Weighted-Average | | Aggregate Intrinsic Value ^(a) (MILLIONS) |
|---------------------------------|-----------|-----------------------------|--|--|
| | | Exercise Price Per Share | Remaining Contractual Term (Years) | |
| Outstanding, December 31, 2012 | — | \$ — | | |
| Granted | 2,994,295 | 26.11 | | |
| Exercised | (6,419) | 26.00 | | |
| Forfeited | (60,559) | 26.02 | | |
| Outstanding, September 29, 2013 | 2,927,317 | \$ 26.11 | 9.4 | \$15 |
| Exercisable, September 29, 2013 | 4,992 | \$ 26.00 | 9.3 | — |

^(a) Market price of underlying Zoetis common stock less exercise price.

The following table summarizes data related to stock option activity:

| | Nine Months Ended/As of September 29, 2013 |
|---|---|
| (MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS) | |
| Weighted-average grant date fair value per stock option | \$7.05 |
| Total compensation cost related to nonvested stock options not yet recognized, pre-tax | \$14 |
| Weighted-average period over which stock option compensation is expected to be recognized (years) | 2.0 |

D. Restricted Stock Units (RSUs)

RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs vest after three years of continuous service from the grant date and the values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.

The following table provides an analysis of RSU activity for the nine months ended September 29, 2013:

| | Shares | Weighted-Average |
|------------------------------|---------|---------------------------------------|
| | | Grant Date Fair Value Per Share |
| Nonvested, December 31, 2012 | — | \$ — |
| Granted | 979,611 | 26.81 |

Edgar Filing: Zoetis Inc. - Form 10-Q

| | | | |
|---------------------------------|---------|---|----------|
| Vested | (661 |) | 26.00 |
| Reinvested dividend equivalents | 3,314 | | 26.16 |
| Forfeited | (19,890 |) | 26.23 |
| Nonvested, September 29, 2013 | 962,374 | | \$ 26.82 |

18 |

Table of Contents

The follow table provides data related to RSU activity:

| | |
|---|---|
| | Nine Months Ended/As of September 29, 2013 |
| (MILLIONS OF DOLLARS) | |
| Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax | \$21 |
| Weighted-average period over which RSU cost is expected to be recognized (years) | 2.3 |

E. Deferred Stock Units (DSUs)

DSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. DSUs vest immediately as of the grant date and the values are expensed at the time of grant into Selling, general and administrative expenses.

For the nine months ended September 29, 2013, Zoetis granted 34,804 DSUs at a grant date weighted-average fair value of \$28.15 per stock unit. There were 34,870 DSUs outstanding, including dividend equivalents, as of September 29, 2013.

F. Treatment of Outstanding Pfizer Equity Awards

Following the IPO, the equity awards previously granted to our employees by Pfizer continued to vest, and service with Zoetis counted as service with Pfizer for equity award purposes. On June 24, 2013, Pfizer completed the Exchange Offer whereby Pfizer disposed of all of its shares of Zoetis common stock owned by Pfizer. Pfizer accelerated the vesting of, and in some cases the settlement of, on a pro-rata basis, outstanding Pfizer RSUs, Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) previously granted to our employees, subject, in each case, to the requirements of Section 409A of the U.S. Internal Revenue Code, the terms of the 2004 Pfizer Stock Plan and the applicable award agreements and any outstanding deferral elections. In addition, unvested Pfizer stock options previously granted to our employees accelerated in full, and our employees generally have the ability to exercise the stock options until the earlier of (i) June 23, 2016 (three years from Pfizer's completion of the Exchange Offer), (ii) termination of employee from Zoetis, or (iii) the expiration date of the stock option. Zoetis employees who held Pfizer stock options and were retirement eligible as of June 24, 2013 will have the full term of the stock option to exercise.

The accelerated vesting of the outstanding Pfizer stock options, and the settlement, on a pro-rata basis, of other Pfizer equity awards, resulted in the recognition of additional expense for the nine months ended September 29, 2013 of \$9 million, which is included in stock-based compensation. The unvested portion of Pfizer RSUs, TSRUs and PSAs were forfeited as of the completion of the Exchange Offer. In the third quarter of 2013, Zoetis made a cash payment of approximately \$20 million to certain non-executive Zoetis employees, based on the value of the employees' forfeited Pfizer RSUs, TSRUs and PSAs (as applicable). This amount is included in the condensed consolidated statements of income as additional compensation expense for the nine months ended September 29, 2013. Members of the Zoetis Executive Team did not receive a cash payment for any forfeited Pfizer RSUs, TSRUs and PSAs, but instead, in the third quarter of 2013, they were granted Zoetis RSUs which were equivalent in value and vest on the same date as their forfeited Pfizer RSUs, TSRUs and PSAs.

14. Earnings per Share

The following table presents the calculation of basic and diluted earnings per share:

| | Three Months Ended | | Nine Months Ended | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) | | | | |
| Numerator | | | | |
| Net income before allocation to noncontrolling interests | \$131 | \$161 | \$399 | \$446 |
| Less: net income attributable to noncontrolling interests | — | (1 |) | — |
| Net income attributable to Zoetis Inc. | \$131 | \$162 | \$399 | \$446 |
| Denominator | | | | |

Edgar Filing: Zoetis Inc. - Form 10-Q

| | | | | |
|---|---------|---------|---------|---------|
| Weighted-average common shares outstanding | 500.000 | 500.000 | 500.000 | 500.000 |
| Common stock equivalents: stock options, RSUs and DSUs | 0.354 | — | 0.227 | — |
| Weighted-average common and potential dilutive shares outstanding | 500.354 | 500.000 | 500.227 | 500.000 |
| Earnings per share attributable to Zoetis Inc. stockholders—basic | \$0.26 | \$0.32 | \$0.80 | \$0.89 |
| Earnings per share attributable to Zoetis Inc. stockholders—diluted | \$0.26 | \$0.32 | \$0.80 | \$0.89 |

15. Commitments and Contingencies

We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 7. Income Taxes.

Table of Contents

A. Legal Proceedings

Our non-tax contingencies include, among others, the following:

• Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.

• Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.

• Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.

• Government investigations, which can involve regulation by national, state and local government agencies in the United States and in other countries.

Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.

We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.

We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.

Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader's judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.

Roxarsone®(3-Nitro)

We are defendants in nine actions involving approximately 140 plaintiffs that allege that the distribution of the medicated feed additive Roxarsone allegedly caused various diseases in the plaintiffs, including cancers and neurological diseases. Other defendants, including various poultry companies, are also named in these lawsuits.

Compensatory and punitive damages are sought in unspecified amounts.

In September 2006, the Circuit Court of Washington County returned a defense verdict in one of the lawsuits, Mary Green, et al. v. Alpharma, Inc. et al. In 2008, this verdict was appealed and affirmed by the Arkansas Supreme Court. Certain summary judgments favoring the poultry company co-defendants in Mary Green, et al. v. Alpharma, Inc. et al. were reversed by the Arkansas Supreme Court in 2008. These claims were retried in 2009 and that trial also resulted in a defense verdict, which was affirmed by the Arkansas Supreme Court in April 2011. In October 2012, we entered into an agreement to resolve these cases. The resolution is subject to the execution of full releases or dismissals with prejudice by all of the claimants or our waiver of these requirements. The trial schedule has been suspended pending the outcome of the proposed settlement.

In June 2011, we announced that we would suspend sales in the U.S. of Roxarsone (3-Nitro) in response to a request by the U.S. FDA and subsequently stopped sales in several international markets.

Following our decision to suspend sales of Roxarsone (3-Nitro) in June 2011, Zhejiang Rongyao Chemical Co., Ltd., the supplier of certain materials used in the production of Roxarsone (3-Nitro), filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that we are liable for damages it suffered as a result of the decision to suspend sales. No trial date has been set and the parties are exploring possible settlement.

PregSure®

We have received in total approximately 80 claims in Europe and New Zealand seeking damages related to calves claimed to have died of Bovine Neonatal Pancytopenia (BNP) on farms where PregSure BVD, a vaccine against Bovine Virus Diarrhea (BVD) was used. BNP is a rare syndrome that first emerged in cattle in Europe in 2006. Studies of BNP suggest a potential association between the administration of PregSure and the development of BNP, although no causal connection has been established. The cause of BNP is not known.

Table of Contents

In 2010, we voluntarily stopped sales of PregSure BVD in Europe, and recalled the product at wholesalers while investigations into possible causes of BNP continue. In 2011, after incidences of BNP were reported in New Zealand, we voluntarily withdrew the marketing authorization for PregSure throughout the world.

We have settled approximately 20 of these claims for amounts that are not material individually or in the aggregate. Investigations into possible causes of BNP continue and these settlements may not be representative of any future claims resolutions.

Advocin

On January 30, 2012, Bayer filed a complaint against Pfizer alleging infringement and inducement of infringement of Bayer patent US 5,756,506 covering, among other things, a process for treating bovine respiratory disease (BRD) by administering a single high dose of fluoroquinolone. The complaint was filed after Pfizer's product Advocin[®] was approved as a single dose treatment of BRD, in addition to its previous approval as a multi-dose treatment of BRD. Bayer seeks a permanent injunction, damages and a recovery of attorney's fees, and has demanded a jury trial. Discovery has now concluded. We have filed motions for summary judgment of non-infringement and invalidity of the Bayer patent, which are currently pending before the Court.

Ulianopolis, Brazil

In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL) and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.

The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.

At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility.

In early August 2013, new labor claims were filed against FDSAL as well as 57 other companies. These claims were filed by 30 employees of the local waste incineration facility that was used by FDSAL and the 57 other companies. The employees of the incineration facility allege health injuries in connection with their employment at the waste site. Based on legal precedent, it is possible that FDSAL may be considered a liable party. Due to the fact that we are in the early stages of discovery, the amount of a potential loss, if any, cannot be reasonably estimated.

Counsel has advised that the likelihood of Zoetis being considered severally liable is remote.

Other Matters

The European Commission published a decision on alleged competition law infringements by several human health pharmaceutical companies on June 19, 2013. One of the involved legal entities is Zoetis Products LLC, formerly having the name Alphanma Inc. Zoetis Products LLC's involvement is solely related to its human health activities prior to Pfizer's acquisition of King/Alphanma. The fine imposed on Zoetis Products LLC amounts to Euro 11 million (approximately \$14 million). Under the Global Separation Agreement between Pfizer and Zoetis, Pfizer is obligated to indemnify Zoetis for any liabilities arising out of claims not related to its animal health assets. A liability of \$14 million is included in Other current liabilities and a corresponding receivable from Pfizer of \$14 million is included in Other current assets as of September 29, 2013. We filed an appeal of the decision on September 6, 2013.

B. Guarantees and Indemnifications

In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 29, 2013, recorded amounts for the estimated fair

value of these indemnifications are not significant.

16. Segment and Other Revenue Information

A. Segment Information

The animal health medicines and vaccines industry is characterized by meaningful differences in customer needs across different regions. As a result of these differences, among other things, we manage our operations through four geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these regional operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceuticals, for both livestock and companion animal customers.

Operating Segments

• The United States (U.S.).

21 |

Table of Contents

Europe/Africa/Middle East (EuAfME)—Includes, among others, the United Kingdom, Germany, France, Italy, Spain, Northern Europe and Central Europe as well as Russia, Turkey and South Africa.

Canada/Latin America (CLAR)—Includes Canada, Brazil, Mexico, Central America and Other South America.

Asia/Pacific (APAC)—Includes Australia, Japan, New Zealand, South Korea, India, China/Hong Kong, Northeast Asia, Southeast Asia and South Asia.

Our chief operating decision maker uses the revenue and earnings of the four operating segments, among other factors, for performance evaluation and resource allocation.

Other Costs and Business Activities

Certain costs are not allocated to our operating segment results, such as costs associated with the following:

Research & development (R&D), which is generally responsible for research projects.

Corporate, which is responsible for platform functions such as business technology, facilities, legal, finance, human resources, business development, public affairs and procurement, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.

Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) acquisition-related activities, where we incur costs for restructuring and integration; and (iii) certain significant items, which include non-acquisition-related restructuring charges, certain asset impairment charges and costs associated with cost reduction/productivity initiatives.

Segment Assets

We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately \$6.3 billion at both September 29, 2013 and December 31, 2012.

Table of Contents

Selected Statement of Income Information

| | Revenue ^(a) | | Earnings ^(b) | | Depreciation and Amortization ^(c) | |
|--|------------------------|--------------------|-------------------------|--------------------|--|--------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | | | | | |
| Three months ended | | | | | | |
| U.S. | \$495 | \$448 | \$285 | \$232 | \$11 | \$11 |
| EuAfME | 270 | 241 | 92 | 91 | 5 | 9 |
| CLAR | 171 | 165 | 56 | 53 | 5 | 5 |
| APAC | 167 | 165 | 57 | 59 | 4 | 6 |
| Total reportable segments | 1,103 | 1,019 | 490 | 435 | 25 | 31 |
| Other business activities ^(d) | — | — | (80) | (65) | 6 | 4 |
| Reconciling Items: | | | | | | |
| Corporate ^(e) | — | — | (139) | (113) | 1 | 1 |
| Purchase accounting adjustments ^(f) | — | — | (12) | (13) | 12 | 13 |
| Acquisition-related costs ^(g) | — | — | (1) | (5) | — | 5 |
| Certain significant items ^(h) | — | — | (46) | (11) | — | — |
| Other unallocated ⁽ⁱ⁾ | — | — | (27) | (15) | 5 | — |
| | \$1,103 | \$1,019 | \$185 | \$213 | \$49 | \$54 |
| Nine Months Ended | | | | | | |
| U.S. | \$1,386 | \$1,294 | \$773 | \$676 | \$33 | \$26 |
| EuAfME | 838 | 799 | 300 | 283 | 17 | 21 |
| CLAR | 555 | 549 | 186 | 184 | 14 | 17 |
| APAC | 528 | 518 | 203 | 193 | 10 | 13 |
| Total reportable segments | 3,307 | 3,160 | 1,462 | 1,336 | 74 | 77 |
| Other business activities ^(d) | — | — | (228) | (191) | 19 | 12 |
| Reconciling Items: | | | | | | |
| Corporate ^(e) | — | — | (392) | (346) | 16 | 18 |
| Purchase accounting adjustments ^(f) | — | — | (37) | (39) | 37 | 39 |
| Acquisition-related costs ^(g) | — | — | (17) | (34) | — | 10 |
| Certain significant items ^(h) | — | — | (130) | (28) | — | — |
| Other unallocated ⁽ⁱ⁾ | — | — | (94) | (62) | 5 | — |
| | \$3,307 | \$3,160 | \$564 | \$636 | \$151 | \$156 |

Revenue denominated in euros were \$159 million and \$493 million in the three and nine months ended September 29, 2013, respectively and \$142 million and \$464 million in the three and nine months ended September 30, 2012, respectively.

(b) Defined as income before provision for taxes on income.

(c) Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.

(d) Other business activities reflect the research and development costs managed by our Research and Development organization.

(e) Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.

(f) Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(g) Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

(h) Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, the impact of divestiture-related gains and losses and certain costs related to becoming a standalone public company. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives.

In the third quarter of 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of \$41 million; and (ii) litigation-related charges of \$5 million. Stand-up costs include certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, accelerated vesting and associated cash payment related to certain Pfizer equity awards, and certain legal registration and patent assignment costs.

Table of Contents

In the third quarter of 2012, certain significant items includes: (i) charges related to transitional manufacturing purchase agreements associated with divestitures of \$1 million and (ii) \$10 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.

In the nine months ended September 29, 2013, certain significant items primarily includes: (i) Zoetis stand-up costs of \$152 million; (ii) \$26 million income related to a reversal of certain employee termination expenses; (iii) \$6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of \$3 million; and (v) litigation-related charges of \$5 million.

In the nine months ended September 30, 2012, certain significant items includes: (i) \$14 million income related to a favorable legal settlement for an intellectual property matter; (ii) \$4 million income due to a change in estimate related to transitional manufacturing purchase agreements associated with divestitures; and (iii) \$46 million for restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition.

(i) Includes overhead expenses associated with our manufacturing operations.

B. Other Revenue Information**Revenue by Species**

Significant species revenue are as follows:

| | Three Months Ended | | Nine Months Ended | |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | | | |
| Livestock: | | | | |
| Cattle | \$388 | \$365 | \$1,134 | \$1,136 |
| Swine | 155 | 140 | 465 | 425 |
| Poultry | 134 | 125 | 404 | 375 |
| Other | 29 | 29 | 79 | 79 |
| | 706 | 659 | 2,082 | 2,015 |
| Companion Animal: | | | | |
| Horses | 37 | 35 | 124 | 130 |
| Dogs and Cats | 360 | 325 | 1,101 | 1,015 |
| | 397 | 360 | 1,225 | 1,145 |
| Total revenue | \$1,103 | \$1,019 | \$3,307 | \$3,160 |

Revenue by Major Product Category

Significant revenue by major product category are as follows:

| | Three Months Ended | | Nine Months Ended | |
|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| (MILLIONS OF DOLLARS) | | | | |
| Anti-infectives | \$333 | \$299 | \$920 | \$882 |
| Vaccines | 298 | 266 | 877 | 812 |
| Parasiticides | 167 | 155 | 544 | 532 |
| Medicated feed additives | 93 | 105 | 294 | 298 |
| Other pharmaceuticals | 177 | 165 | 558 | 529 |
| Other non-pharmaceuticals | 35 | 29 | 114 | 107 |
| Total revenue | \$1,103 | \$1,019 | \$3,307 | \$3,160 |

Table of Contents

17. Transactions and Agreements with Pfizer

Zoetis had related party transactions with Pfizer through the completion of the Exchange Offer on June 24, 2013. As of the completion of the Exchange Offer, Pfizer is no longer a related party. Activities while Pfizer was a related party, as well as ongoing agreements with Pfizer, are detailed below.

A. Pre-Separation Period

For the condensed combined statement of income for the three and nine months ended ended September 30, 2012, the costs of goods manufactured in manufacturing plants that were shared with other Pfizer business units was approximately \$105 million and \$320 million, respectively.

In the pre-Separation period, Pfizer provided significant corporate, manufacturing and shared services functions and resources to us. Our condensed combined financial statements as of and for the three and nine months ended ended September 30, 2012, respectively, reflect an allocation of these costs. For further information about the cost allocations for these services and resources, see Note 3A. Basis of Presentation: Basis of Presentation Prior to the Separation. Management believes that these allocations are a reasonable reflection of the services received. However, these allocations may not reflect the expenses that would have been incurred if we had operated as a standalone public company for the period presented.

Pfizer uses a centralized approach to cash management and financing its operations. In the pre-Separation period, cash deposits were remitted to Pfizer on a regular basis and were reflected in business unit equity and, similarly, Zoetis's cash disbursements were funded through Pfizer's cash accounts and were reflected within Business unit equity.

B. Agreements with Pfizer

In connection with the Separation and IPO, we and Pfizer entered into agreements that provide a framework for our ongoing relationship with Pfizer, certain of which are described below.

Global separation agreement. This agreement governs the relationship between Pfizer and us following the IPO and includes provisions related to the allocation of assets and liabilities, indemnification, delayed transfers and further assurances, mutual releases, insurance and certain covenants.

Transitional services agreement. This agreement grants us the right to continue to use certain of Pfizer's services and resources related to our corporate functions, such as business technology, facilities, finance, human resources, public affairs and procurement, in exchange for mutually agreed-upon fees based on Pfizer's costs of providing these services.

Tax matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. Pursuant to this agreement, we have also agreed to certain covenants that contain restrictions intended to preserve the tax-free status of certain transactions, and we have agreed to indemnify Pfizer and its affiliates against any and all tax-related liabilities incurred by them relating to these transactions to the extent caused by an acquisition of our stock or assets or by any other action undertaken by us.

Research and development collaboration and license agreement. This agreement permits certain of our employees to be able to review a Pfizer database to identify compounds that may be of interest to the animal health field. Pfizer has granted to us an option to enter into a license agreement subject to certain restrictions and requirements and we will make payments to Pfizer.

Employee matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to the following matters: employees and former employees (and their respective dependents and beneficiaries) who are or were associated with Pfizer, us or the parties' respective subsidiaries or affiliates; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; and other human resources, employment and employee benefits matters.

Master manufacturing and supply agreements. These two agreements govern our manufacturing and supply arrangements with Pfizer. Under one of these agreements, Pfizer will manufacture and supply us with animal health products. Under this agreement, our manufacturing and supply chain leadership will have oversight responsibility over product quality and other key aspects of the manufacturing process with respect to the Pfizer-supplied products. Under the other agreement, we will manufacture and supply certain human health products to Pfizer.

Environmental matters agreement. This agreement governs the performance of remedial actions for liabilities allocated to each party under the global separation agreement; addresses our substitution for Pfizer with respect to animal health assets and remedial actions allocated to us (including substitution related to, for example, permits, financial assurances and consent orders); allows our conditional use of Pfizer's consultants and contractors to assist in the conduct of remedial actions; and addresses the exchange of related information between the parties. The agreement also sets forth standards of conduct for remedial activities at the co-located facilities: Guarulhos, Brazil; Catania, Italy; Hsinchu, Taiwan; and Kalamazoo, Michigan in the U.S. In addition, the agreement sets forth site-specific terms to govern conduct at several of these co-located facilities.

Screening services agreement. This agreement requires us to provide certain high throughput screening services to Pfizer's R&D organization for which Pfizer pays to us agreed-upon fees.

Table of Contents

Intellectual property license agreements. Under these agreements (i) Pfizer and certain of its affiliates licensed to us and certain of our affiliates the right to use certain intellectual property rights in the animal health field; (ii) we licensed to Pfizer and certain of its affiliates certain rights to intellectual property in all fields outside of the animal health field; and (iii) Pfizer granted us rights with respect to certain trademarks and copyrighted works.

Following the Separation, we own, have access to or have the right to use, substantially all of the resources that were used, or held for use, exclusively in Pfizer's animal health business, including the following:

Intellectual Property. As part of the Separation, Pfizer assigned to us ownership of certain animal health related patents, pending patent applications, and trademark applications and registrations. In addition, Pfizer licensed to us the right to use certain intellectual property rights in the animal health field. We licensed to Pfizer the right to use certain of our trademarks and substantially all of our other intellectual property rights in the human health field and all other fields outside of animal health. In addition, Pfizer granted us a transitional license to use certain of Pfizer's trademarks and we granted Pfizer a transitional license to use certain of our trademarks for a period of time following the completion of the IPO.

Manufacturing Facilities. Our global manufacturing network consists of 13 “anchor” manufacturing sites and 16 “satellite” manufacturing sites. Ownership of, or the existing leasehold interest in, these facilities were conveyed to us by Pfizer as part of the Separation. Among these 29 manufacturing sites is our facility in Guarulhos, Brazil, which we leased back to Pfizer. Certain of our products are currently manufactured at 14 manufacturing sites that were retained by Pfizer. The products manufactured by Pfizer at these sites and at our Guarulhos, Brazil facility continue to be supplied to us under the terms of a manufacturing and supply agreement we entered into with Pfizer.

R&D Facilities. We have R&D operations co-located with certain of our manufacturing sites in Australia, Belgium, Brazil, Canada, China, Spain and the United States to facilitate the efficient transfer of production processes from our laboratories to manufacturing sites. In addition, we maintain R&D operations at non-manufacturing locations in Belgium, Brazil, India and the United States. As part of the Separation, Pfizer conveyed to us its interest in each of these R&D facilities, with the exception of our Mumbai, India facility, which we expect Pfizer to transfer to us after the completion of the Separation for cash consideration to be agreed upon, and, in the interim, we are leasing this facility from Pfizer.

Employees. In general, as part of the Separation, employees of Pfizer who were substantially dedicated to the animal health business became our employees. However, labor and employment laws or other business considerations in some jurisdictions delayed Pfizer from transferring to us employees who are substantially dedicated to the animal health business. In those instances, to the extent permissible under applicable law, we and Pfizer entered into mutually-acceptable arrangements to provide for continued operation of the business until such time as the employees in those jurisdictions can be transferred to us.

The amounts charged under each of the agreements with Pfizer, through the completion of the Exchange Offer on June 24, 2013, were as follows:

(MILLIONS OF DOLLARS)

| | |
|--|------|
| Transitional services agreement | \$63 |
| Master manufacturing and supply agreements | 130 |
| Employee matters agreement | 99 |

In certain jurisdictions, while the Zoetis entities obtain appropriate registration and licensing, Pfizer entities purchase product from Zoetis entities and resell such product to the local Zoetis entity at cost. This activity is reflected in Accounts receivable for the product Pfizer purchases from Zoetis entities and in Accounts payable for the product purchased from such Pfizer entities by our local Zoetis entity.

We remained part of Pfizer's consolidated U.S. tax returns until we fully separated on June 24, 2013, and therefore reflected 2013 U.S. income taxes payable of \$31 million as a payable to Pfizer in Other current liabilities.

Table of Contents

Review Report of Independent Registered Public Accounting Firm

The Board of Directors

Zoetis Inc.:

We have reviewed the accompanying condensed consolidated balance sheet of Zoetis Inc. and subsidiaries (the Company) as of September 29, 2013, the related condensed consolidated statements of income and comprehensive income for the three-month and nine-month periods ended September 29, 2013, the related condensed consolidated statements of equity and cash flows for the nine-month period ended September 29, 2013, the related condensed combined statements of income and comprehensive income for the three-month and nine-month periods ended September 30, 2012, and the related condensed combined statements of equity and cash flows for the nine-month period ended September 30, 2012. These condensed consolidated and condensed combined financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole.

Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements as of September 29, 2013 and for the three-month and nine-month periods ended September 29, 2013 and to the condensed combined financial statements for the three-month and nine-month periods ended September 30, 2012 referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), the combined balance sheet of Zoetis Inc. (the animal health business unit of Pfizer Inc.) as of December 31, 2012, and the related combined statements of income, comprehensive income, equity, and cash flows for the year then ended (not presented herein); and in our report dated March 28, 2013, we expressed an unqualified opinion on those combined financial statements. In our opinion, the information set forth in the accompanying condensed combined balance sheet as of December 31, 2012, is fairly stated, in all material respects, in relation to the combined balance sheet from which it has been derived.

/s/ KPMG LLP

New York, New York

November 13, 2013

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

Introduction

Our MD&A is provided in addition to the accompanying condensed consolidated and combined financial statements and notes to assist readers in understanding the results of operations, comprehensive income, financial condition and cash flows of Zoetis Inc. (Zoetis). This MD&A is organized as follows:

| Section | Description | Page |
|--|---|-----------|
| Overview of our business | A general description of our business and the industry in which we operate. For more information regarding our business and the animal health industry, see Item 1. Business of our 2012 Annual Report on Form 10-K. | <u>28</u> |
| Our operating environment | Information regarding the animal health industry and factors that affect our company. | <u>29</u> |
| Comparability of historical results and our relationship with Pfizer | Information about the limitations of the predictive value of the condensed consolidated and combined financial statements. | <u>31</u> |
| Analysis of the condensed consolidated and combined statements of income | Consists of the following for all periods presented: | |
| | • Revenue: An analysis of our revenue in total. | <u>33</u> |
| | • Costs and expenses: A discussion about the drivers of our costs and expenses. | <u>33</u> |
| Adjusted net income | • Operating segment results: A discussion of our revenue by operating segment and species and items impacting our earnings before income tax. | <u>38</u> |
| | A discussion of adjusted net income, an alternative view of performance used by management. Adjusted net income is a non-GAAP financial measure. | <u>43</u> |
| Our financial guidance for 2013 | A discussion of our 2013 financial guidance. | <u>47</u> |
| Analysis of the condensed consolidated and combined statements of comprehensive income | An analysis of the components of comprehensive income for all periods presented. | <u>47</u> |
| Analysis of the condensed consolidated and combined balance sheets | A discussion of changes in certain balance sheet accounts for all balance sheets presented. | <u>48</u> |
| Analysis of the condensed consolidated and combined statements of cash flows | An analysis of the drivers of our operating, investing and financing cash flows for all periods presented. | <u>48</u> |
| Analysis of financial condition, liquidity and capital resources | An analysis of our ability to meet our short-term and long-term financing needs. | <u>49</u> |
| New accounting standards | Accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted. | <u>51</u> |
| | A description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements set forth in this MD&A relating to our financial and operating performance, business plans and prospects, strategic review, capital allocation and business-development plans. Such forward-looking statements are based on management's current expectations about future events, which are inherently susceptible to uncertainty and changes in circumstances. | <u>52</u> |

Overview of our business

We are a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. For more than 60 years, as a business unit of Pfizer Inc. (Pfizer) and now as a standalone public company, we have been committed to enhancing the health of animals and bringing solutions to our customers who raise and care for them.

The animal health medicines and vaccines industry is characterized by meaningful differences in customer needs across different regions. As a result of these differences, among other things, we manage our operations through four geographic operating segments. Within each of these operating segments, we offer a diversified product portfolio for both livestock and companion animal customers in order to capitalize on local and regional trends and customer needs. Our four operating segments are the United States (U.S.), Europe/Africa/Middle East (EuAfME), Canada/Latin America (CLAR) and Asia/Pacific (APAC). See Notes to Condensed Consolidated and Combined Financial Statements—Note 16. Segment and Other Revenue Information.

We directly market our products to livestock producers and veterinarians located in approximately 70 countries across North America, Europe, Africa, Asia, Australia and Latin America, and are a market leader in nearly all of the major regions in which we operate. Through our efforts to establish an early and direct presence in many emerging markets, such as Brazil, China and India, we believe we are the largest animal health medicines and vaccines business as measured by revenue across emerging markets as a whole. In markets where we do not have a direct commercial presence, we generally contract with distributors that provide logistics and sales and marketing support for our products.

28 |

Table of Contents

We believe our investments in the industry's largest sales organization, including our extensive network of technical and veterinary operations specialists, our high-quality manufacturing and reliability of supply, and our long track record of developing products that meet customer needs, has led to enduring and valued relationships with our customers. Our R&D efforts enable us to deliver innovative products to address unmet needs and evolve our product lines so they remain relevant for our customers.

A summary of our 2013 performance compared to the comparable 2012 period follows:

| | Three Months Ended | | | Nine Months Ended | | |
|------------------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Revenue | \$1,103 | \$1,019 | 8 | \$3,307 | \$3,160 | 5 |
| Net income attributable to Zoetis | 131 | 162 | (19) | 399 | 446 | (11) |
| Adjusted net income ^(a) | 172 | 154 | 12 | 529 | 482 | 10 |

^(a) Adjusted net income is a non-GAAP financial measure. See the "Adjusted net income" section of this MD&A for more information.

Our ownership

On February 6, 2013, an initial public offering (IPO) of our Class A common stock was completed, which represented approximately 19.8% of our total outstanding shares. Following the IPO, Pfizer owned 100% of our outstanding Class B common stock and no shares of our Class A common stock, giving Pfizer 80.2% of the economic interest and the combined voting power in shares of our outstanding common stock other than with respect to the election of directors and 97.6% of the combined voting power of our outstanding common stock with respect to the election of directors.

On February 1, 2013, our Class A common stock began trading on the New York Stock Exchange under the symbol "ZTS." Prior to and in connection with the IPO, we completed a \$3.65 billion senior notes offering and Pfizer transferred to us substantially all of the assets and liabilities of their animal health business. We refer to the transactions to separate our business from Pfizer as described here and elsewhere in this quarterly report as the Separation.

On May 22, 2013, Pfizer announced an exchange offer whereby Pfizer shareholders could exchange a portion of Pfizer common stock for Zoetis common stock. The Exchange Offer was completed on June 24, 2013, resulting in the full separation of Zoetis and the disposal of Pfizer's entire ownership and voting interest. Following the Exchange Offer, there are no shares of our Class B common stock outstanding.

Our operating environment**Industry**

The animal health industry, which focuses on both livestock and companion animals, is a growing industry that impacts billions of people worldwide. The primary livestock species for the production of animal protein are cattle (both beef and dairy), swine, poultry, sheep and fish. Livestock health and production are essential to meeting the growing demand for animal protein of a global population. Factors influencing growth in demand for livestock medicines and vaccines include:

- human population growth and increasing standards of living, particularly in many emerging markets;
- increasing demand for improved nutrition, particularly animal protein;
- natural resource constraints, such as scarcity of arable land, fresh water and increased competition for cultivated land, resulting in fewer resources that will be available to meet this increased demand for animal protein; and
- increased focus on food safety.

The primary companion animal species are dogs, cats and horses. Health professionals indicate that companion animals improve the physical and emotional well-being of pet owners. Factors influencing growth in demand for companion animal medicines and vaccines include:

- economic development and related increases in disposable income, particularly in many emerging markets;
- increasing pet ownership; and
- companion animals living longer, increasing medical treatment of companion animals and advances in companion animal medicines and vaccines.

Product development initiatives

Our future success depends on both our existing product portfolio and our pipeline of new products, including new products that we may develop through joint ventures and products that we are able to obtain through license or acquisition. We believe we are an industry leader in animal health R&D, with a track record of generating new products and brand lifecycle developments. The majority of our R&D programs focus on brand lifecycle development, which is defined as R&D programs that leverage existing animal health products by adding new species or claims, achieving approvals in new markets or creating new combinations and reformulations.

29 |

Table of Contents

Perceptions of product quality, safety and reliability

We believe that animal health medicines and vaccines customers value high-quality manufacturing and reliability of supply. The importance of quality and safety concerns to pet owners, veterinarians and livestock producers also contributes to animal health brand loyalty, which we believe often continues after the loss of patent-based and regulatory exclusivity. We depend on positive perceptions of the safety and quality of our products, and animal health products generally, by our customers, veterinarians and end-users.

The issue of the potential transfer of increased antibacterial resistance in bacteria from food-producing animals to human pathogens, and the causality of that transfer, are the subject of global scientific and regulatory discussion. In some countries, this issue has led to government restrictions and bans on the use of specific antibacterials in some food-producing animals, regardless of the route of administration (topical, oral, intramuscular/subcutaneous injections, or intravenous). These restrictions are more prevalent in countries where animal protein is plentiful and governments are willing to take restrictive actions even when there is scientific uncertainty. Historically, antibacterials for livestock have represented a significant portion of our revenue. We cannot predict whether antibacterial resistance concerns will result in additional restrictions or bans, expanded regulations or public pressure to discontinue or reduce use of antibacterials in food-producing animals.

The overall economic environment

In addition to industry-specific factors, we, like other businesses, continue to face the effects of the current challenging economic environment. Growth in both the livestock and companion animal sectors is driven by overall economic development and related growth, particularly in many emerging markets. Certain of our customers and suppliers have been affected directly by the economic downturn, which decreases the demand for our products and hinders our ability to collect amounts due from customers.

The cost of medicines and vaccines to our livestock producer customers is small relative to other production costs, including feed, and the use of these products are intended to improve livestock producers' economic outcomes. As a result, historically demand for our products has often been more stable than demand for other production inputs. Similarly, industry sources have reported that pet owners indicated a preference for reducing spending on other aspects of their lifestyle, including entertainment, clothing and household goods, before reducing spending on pet care. While these factors have mitigated the impacts of the challenging economic environment, the impact of difficult macroeconomic conditions increases over time.

Competition

The animal health industry is competitive. Although our business is the largest by revenue in the animal health medicines and vaccines industry, we face competition in the regions and sectors in which we compete. Principal methods of competition vary depending on the particular region, species, product category or individual product. Some of these methods include new product development, quality, price, service and promotion to veterinary professionals, pet owners and livestock producers. Our competitors include the animal health businesses of large pharmaceutical companies and specialty animal health businesses. In addition to competition from established market participants, there could be new entrants to the animal health medicines and vaccines industry in the future. In certain markets, we also compete with companies that produce generic products, but the level of competition from generic products varies from market to market. For example, the level of generic competition is higher in Europe and certain emerging markets than in the U.S.

Quarterly Variability of Financial Results

Our quarterly financial results are subject to variability related to a number of factors including but not limited to: weather patterns, herd management decisions, economic conditions, regulatory actions, competitive dynamics, disease outbreaks, product and geographic mix, timing of price increases and timing of investment decisions.

Weather conditions and the availability of natural resources

The animal health industry and demand for many of our animal health products in a particular region are affected by weather conditions, as usage of our products follows varying weather patterns and weather-related pressures from pests, such as ticks. As a result, we may experience regional and seasonal fluctuations in our results of operations. In addition, livestock producers depend on the availability of natural resources, including large supplies of fresh water. Their animals' health and their ability to operate could be adversely affected if they experience a shortage of fresh

water due to human population growth or floods, droughts or other weather conditions. In the event of adverse weather conditions or a shortage of fresh water, livestock producers may purchase less of our products. For example, drought conditions could negatively impact, among other things, the supply of corn and the availability of grazing pastures. A decrease in harvested corn results in higher corn prices, which could negatively impact the profitability of livestock producers of cattle, pork and poultry. Higher corn prices and reduced availability of grazing pastures contributes to reductions in herd or flock sizes that in turn results in less spending on animal health products. As such, a prolonged drought could have a material adverse impact on our operating results and financial condition. Factors influencing the magnitude and timing of effects of a drought on our performance include, but may not be limited to, weather patterns and herd management decisions. The drought which has impacted parts of the U.S. over the past two years, is considered the worst in many years and affected our performance in the U.S. market in 2012 and in the first half of 2013.

30 |

Table of Contents

Disease outbreaks

Sales of our livestock products could be adversely affected by the outbreak of disease carried by animals. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. Also, the outbreak of any highly contagious disease near our main production sites could require us to immediately halt production of our products at such sites or force us to incur substantial expenses in procuring raw materials or products elsewhere. Alternatively, sales of products that treat specific disease outbreaks may increase. For example, in 2012, we successfully launched a vaccine for horses against the deadly Hendra virus in Australia.

In 2013, there have been several reported cases of the H7N9 avian influenza virus in China. In late March 2013, the Chinese government reported the first case of the H7N9 avian influenza virus. Since that time, over 100 cases have been detected. We are closely monitoring the developments as this situation unfolds and currently believe the impact on our 2013 global revenue will not be significant. While China continues to represent a growth opportunity for us, sales in this country represented less than 2% of our total revenue in 2012 and the majority was generated by our swine business.

In addition, since the second quarter of 2013 some producers in the U.S. have been experiencing an outbreak of the Porcine Epidemic Diarrhea Virus (PEDV). It is important to note that the virus, which affects piglets, does not create a food safety issue. We are committed to supporting U.S. pork producers in understanding and controlling PEDV, and we are partnering with the stakeholders, including various academic institutions such as the University of Minnesota. Since first reported in the second quarter, the disease has continued to spread and has now been reported in at least 17 U.S. states. We currently believe the impact on our 2013 revenue will not be significant.

Foreign exchange rates

Significant portions of our revenue and costs are exposed to changes in foreign exchange rates. Our products are sold in more than 120 countries and, as a result, our revenues are influenced by changes in foreign exchange rates. For the nine months ended September 29, 2013, approximately 53% of our revenue was denominated in foreign currencies. Prior to the IPO, as a business unit of Pfizer and under Pfizer's global cash management system, our foreign exchange risk was managed through Pfizer. Following the Separation, we seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. As we operate in multiple foreign currencies, including the euro, the Brazilian real, the Australian dollar and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue and expenses, and consequently, net income. Exchange rate fluctuations may also have an impact beyond our reported financial results and directly impact operations. These fluctuations may affect the ability to buy and sell our goods and services between markets impacted by significant exchange rate variances. For the nine months ended September 29, 2013, approximately 47% of our total revenue was in U.S. dollars, and our year-over-year revenue growth was unfavorably impacted by 1% from changes in foreign currency values relative to the U.S. dollar.

On February 13, 2013, the Venezuelan government devalued its currency from a rate of 4.3 to 6.3 Venezuelan bolivars per U.S. dollar. We incurred a foreign currency loss of \$9 million immediately on the devaluation as a result of remeasuring the local assets and liabilities, which is included in Other (income)/deductions—net for the nine months ended September 29, 2013. We will experience ongoing adverse impacts to earnings as our revenue, costs and expenses will be translated into U.S. dollars at lower rates. These impacts are not expected to be significant to our financial condition or results of operations.

Comparability of historical results and our relationship with Pfizer

During the periods covered by the combined financial statements prior to our IPO, we operated solely as a business unit of Pfizer. The combined financial statements have been derived from the consolidated financial statements and accounting records of Pfizer and include allocations for direct costs and indirect costs attributable to the operations of the animal health business of Pfizer. The combined financial statements do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been had we operated as a standalone public company during these periods. In addition, the historical combined financial statements may not be reflective of what our results of operations, comprehensive income/(loss), financial position, equity or cash flows

might be in the future as a standalone public company.

For a detailed description of the basis of presentation and an understanding of the limitations of the predictive value of the historical combined financial statements, see Notes to Condensed Consolidated and Combined Financial Statements—Note 3. Basis of Presentation.

The historical balance sheets may not be comparable to the balance sheet of the standalone company, which reflects the transfer by Pfizer of substantially all of its animal health business to us. Non-comparable elements include, for example, the allocation of Pfizer debt which was not transferred, cash and cash equivalents which were transferred at a predetermined amount, and other assets and liabilities which were not transferred due to legal restrictions and other decisions taken by Pfizer.

Our historical expenses are not necessarily indicative of the expenses we may incur in the future as a standalone public company. With respect to support functions, for example, our historical combined financial statements include expense allocations for certain support functions that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, and, to a lesser extent, business development, public affairs and procurement, among others. As part of the Separation, pursuant to agreements with Pfizer, Pfizer provides us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we are incurring other costs to replace the services and resources that will not be provided by Pfizer. As a standalone public company, our total costs related to such support functions may differ from the costs that were historically allocated to us from Pfizer.

We also expect to incur certain nonrecurring costs related largely to becoming a standalone public company, including new branding (which includes changes to the manufacturing process for required new packaging), the creation of a standalone infrastructure, the implementation of a

Table of Contents

new enterprise resource planning system, the accelerated vesting of Pfizer equity awards, site separation, certain legal registration and patent assignment costs and certain restructuring and other charges. In the second quarter of 2013, these costs were partially offset by the reversal of certain employee termination expenses. In addition, we will also incur certain costs related to the completion of FDAH integration activities. We expect all of the aforementioned nonrecurring costs to range between approximately \$220 million to \$240 million in 2013. These estimates exclude the impact of any depreciation or amortization of capitalized separation expenditures.

Following the IPO, the equity awards previously granted to our employees by Pfizer continued to vest, and service with Zoetis counted as service with Pfizer for equity award purposes. On June 24, 2013, Pfizer completed the Exchange Offer whereby Pfizer disposed of all of its shares of Zoetis common stock owned by Pfizer. Pfizer accelerated the vesting of, and in some cases the settlement of, on a pro-rata basis, outstanding Pfizer RSUs, Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) previously granted to our employees, subject, in each case, to the requirements of Section 409A of the U.S. Internal Revenue Code, the terms of the 2004 Pfizer Stock Plan and the applicable award agreements and any outstanding deferral elections. In addition, unvested Pfizer stock options previously granted to our employees accelerated in full, and our employees generally have the ability to exercise the stock options until the earlier of (i) June 23, 2016 (three years from Pfizer's completion of the Exchange Offer), (ii) termination of employee from Zoetis, or (iii) the expiration date of the stock option. Zoetis employees who held Pfizer stock options and were retirement eligible as of June 24, 2013 will have the full term of the stock option to exercise.

The accelerated vesting of the outstanding Pfizer stock options, and the settlement, on a pro-rata basis, of other Pfizer equity awards, resulted in the recognition of additional expense for the nine months ended September 29, 2013 of \$9 million, which is included in stock-based compensation. The unvested portion of Pfizer RSUs, TSRUs and PSAs were forfeited as of the completion of the Exchange Offer. In the third quarter of 2013, Zoetis made a cash payment of approximately \$20 million to certain non-executive Zoetis employees, based on the value of the employees' forfeited Pfizer RSUs, TSRUs and PSAs (as applicable). This amount is included in the condensed consolidated statements of income as additional compensation expense for the nine months ended September 29, 2013. Members of the Zoetis Executive Team did not receive a cash payment for any forfeited Pfizer RSUs, TSRUs and PSAs, but instead, in the third quarter of 2013, were granted Zoetis RSUs which were equivalent in value and vest on the same date as their forfeited Pfizer RSUs, TSRUs and PSAs.

Public company expenses

As a result of the IPO, we became subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. We have established additional procedures and practices as a standalone public company. As a result, we are incurring additional costs, including, but not limited to, internal audit, investor relations, stock administration and regulatory compliance costs.

Recent significant acquisitions and government-mandated divestitures

The assets, liabilities, operating results and cash flows of acquired businesses are included in our results commencing from their respective acquisition dates.

Delays in establishing new operating subsidiaries

Due to local regulatory and operational requirements in certain non-U.S. jurisdictions, the transfer to us of certain assets and liabilities of Pfizer's animal health business had not yet legally occurred as of the IPO Date. These assets and liabilities were not material to our consolidated financial statements, individually or in the aggregate. As of September 29, 2013, all expected subsidiaries have been established and the related assets and liabilities have transferred.

Agreements with Pfizer

On February 6, 2013, we entered into a transitional services agreement with Pfizer whereby Pfizer agreed to provide us with various corporate support services. This agreement has a service commencement date of January 1, 2013 in the United States and December 1, 2012 for our international locations. In addition, we also entered into a master manufacturing and supply agreement with Pfizer on October 1, 2012, whereby we and Pfizer agreed to manufacture and supply products to each other commencing January 1, 2013. See Notes to Condensed Consolidated and Combined Financial Statements— Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer for more

information related to these and other agreements, including the related costs.

Analysis of the condensed consolidated and combined statements of income

The following discussion and analysis of our statements of income should be read along with our consolidated and combined financial statements and the notes thereto included elsewhere in Part I, Item 1 of this Quarterly Report on Form 10-Q.

32 |

Edgar Filing: Zoetis Inc. - Form 10-Q

| (MILLIONS OF DOLLARS) | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| Revenue | \$1,103 | \$1,019 | 8 | \$3,307 | \$3,160 | 5 |
| Costs and expenses: | | | | | | |
| Cost of sales ^(a) | 385 | 359 | 7 | 1,203 | 1,130 | 6 |
| % of revenue | 35 | % 35 | % | 36 | % 36 | % |
| Selling, general and administrative expenses ^(a) | 399 | 335 | 19 | 1,155 | 1,017 | 14 |
| % of revenue | 36 | % 33 | % | 35 | % 32 | % |
| Research and development expenses ^(a) | 93 | 94 | (1) | 278 | 288 | (3) |
| % of revenue | 8 | % 9 | % | 8 | % 9 | % |
| Amortization of intangible assets ^(a) | 15 | 16 | (6) | 45 | 48 | (6) |
| Restructuring charges and certain acquisition-related costs | 3 | 6 | (50) | (10) | 55 | * |
| Interest expense, net of capitalized interest | 29 | 7 | * | 83 | 23 | * |
| Other (income)/deductions—net | (6) | (11) | (45) | (11) | (37) | (70) |
| Income before provision for taxes on income | 185 | 213 | (13) | 564 | 636 | (11) |
| % of revenue | 17 | % 21 | % | 17 | % 20 | % |
| Provision for taxes on income | 54 | 52 | 4 | 165 | 190 | (13) |
| Effective tax rate | 29.2 | % 24.4 | % | 29.3 | % 29.9 | % |
| Net income before allocation to noncontrolling interests | 131 | 161 | (19) | 399 | 446 | (11) |
| Less: Net income (loss) attributable to noncontrolling interests | — | (1) | — | — | — | — |
| Net income attributable to Zoetis | \$131 | \$162 | (19) | \$399 | \$446 | (11) |
| % of revenue | 12 | % 16 | % | 12 | % 14 | % |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in

(a) Amortization of intangible assets as these intangible assets benefit multiple business functions.

Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate.

Revenue

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Total revenue increased by \$84 million, or 8%, in the third quarter of 2013 compared to the third quarter of 2012, reflecting higher operational revenue of \$95 million or 9%, partially offset by the unfavorable impact of foreign exchange, which decreased revenue by approximately \$11 million, or 1%. We experienced operational growth across each of our regional segments, led by increased revenue in the U.S. and EuAfME segments.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Total revenue increased by \$147 million, or 5%, in the first nine months of 2013 compared to the same period in 2012, reflecting higher operational revenue of \$185 million or 6%, partially offset by the unfavorable impact of foreign exchange, which decreased revenue by approximately \$38 million, or 1%. We experienced operational growth across each of our regional segments, led by increased revenue in the U.S. segment.

Costs and Expenses

Cost of sales

| | Three Months Ended | | | Nine Months Ended | | |
|------------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Cost of sales ^(a) | \$385 | \$359 | 7 | \$1,203 | \$1,130 | 6 |
| % of revenue | 34.9 | % 35.2 | % | 36.4 | % 35.8 | % |

Certain amounts and percentages may reflect rounding adjustments.

Allocation of corporate enabling functions were \$3 million in the first quarter of 2013. Allocation of corporate ^(a) enabling functions were \$0 million and \$1 million in the three and nine months ended September 30, 2012, respectively.

Table of Contents

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Cost of sales increased by \$26 million, or 7%, in the third quarter of 2013 compared to the third quarter of 2012, primarily as a result of:

- revenue growth and product and geographic mix;
 - additional one-time costs of \$3 million related to becoming a standalone public company; and
 - higher costs associated with certain manufacturing agreements related to government-mandated divestitures from prior acquisitions;
- partially offset by:
- operational efficiencies.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Cost of sales increased by \$73 million, or 6%, in the first nine months of 2013 compared to the first nine months of 2012, primarily as a result of:

- revenue growth and product and geographic mix;
 - additional one-time costs of \$18 million related to becoming a standalone public company, including expense of \$2 million due to the accelerated vesting of certain Pfizer equity awards and associated cash payments, as a result of the Separation; and
 - higher costs associated with certain manufacturing agreements related to government-mandated divestitures from prior acquisitions;
- partially offset by:
- operational efficiencies; and
 - lower employee benefit costs due to the termination of the defined benefit pension plan for U.S. employees.

Selling, general and administrative expenses

| | Three Months Ended | | | Nine Months Ended | | |
|---|--------------------|--------------------|----------|--------------------|--------------------|----------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Selling, general and administrative expenses ^(a) | \$399 | \$335 | 19 % | \$1,155 | \$1,017 | 14 % |
| % of revenue | 36 | % 33 | % | 35 | % 32 | % |

Certain amounts and percentages may reflect rounding adjustments.

Allocation of corporate enabling functions were \$24 million in the first quarter of 2013. Allocation of corporate ^(a) enabling functions were \$62 million and \$185 million in the three and nine months ended September 30, 2012, respectively.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Selling, general & administrative (SG&A) expenses increased by \$64 million, or 19%, in the third quarter of 2013 compared to the third quarter of 2012, primarily as a result of:

- additional one-time costs of \$38 million related to becoming a standalone public company;
- partially offset by:
- lower employee benefit costs due to the termination of the defined benefit pension plan for U.S. employees; and
 - favorable foreign exchange.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

SG&A expenses increased by \$138 million, or 14%, in the first nine months of 2013 compared to the first nine months of 2012, primarily as a result of:

- additional one-time costs of \$129 million related to becoming a standalone public company, including expense of \$25 million due to the accelerated vesting of certain Pfizer equity awards and associated cash payments, as a result of the Separation;
- partially offset by:
- lower employee benefit costs due to the termination of the defined benefit pension plan for U.S. employees; and
 - favorable foreign exchange.

Table of Contents

Research and development expenses

| | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Research and development expenses ^(a) | \$93 | \$94 | (1)% | \$278 | \$288 | (3)% |
| % of revenue | 8 | % 9 | % | 8 | % 9 | % |

Certain amounts and percentages may reflect rounding adjustments.

^(a) Allocation of corporate enabling functions were \$15 million and \$43 million in the three and nine months ended September 30, 2012, respectively.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

R&D expenses decreased by \$1 million, or 1%, in the third quarter of 2013 compared to the third quarter of 2012, primarily as a result of

• lower employee benefit costs due to the termination of the defined benefit pension plan for U.S. employees; partially offset by:

• an increase in the volume of R&D activities.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

R&D expenses decreased by \$10 million, or 3%, in the first nine months of 2013 compared to the first nine months of 2012, primarily as a result of:

• the nonrecurrence of depreciation expense incurred in 2012 related to the closing of an R&D facility in the U.K.; and

• lower employee benefit costs due to the termination of the defined benefit pension plan for U.S. employees; partially offset by:

• additional one-time costs of \$5 million related to becoming a standalone public company, including expense of \$4

• million due to the accelerated vesting of certain Pfizer equity awards and associated cash payments, as a result of the Separation; and

• an increase in the volume of R&D activities.

Amortization of intangible assets

| | Three Months Ended | | | Nine Months Ended | | |
|-----------------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Amortization of intangible assets | \$15 | \$16 | (6)% | \$45 | \$48 | (6)% |

Certain amounts and percentages may reflect rounding adjustments.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Amortization of intangible assets decreased by \$1 million, or 6%, in the third quarter of 2013 compared to the third quarter of 2012.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Amortization of intangible assets decreased by \$3 million, or 6%, in the first nine months of 2013 compared to the first nine months of 2012.

Restructuring charges and certain acquisition-related costs

| | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Restructuring charges and certain acquisition-related costs ^(a) | \$3 | \$6 | (50)% | \$(10) | \$55 | * |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

(a) Allocation of Restructuring charges and certain acquisition-related costs were \$12 million and \$47 million in the three and nine months ended September 30, 2012, respectively.

Our acquisition-related costs primarily related to restructuring charges for employees, assets and activities that will not continue in the combined company. The majority of these charges, or reversals, are related to termination costs, but we also exited a number of distributor and other contracts and performed some facility rationalization efforts. Our integration costs are generally comprised of consulting costs related to the integration of systems and processes.

35 |

Table of Contents

The costs associated with our cost reduction/productivity initiatives are predominantly termination costs associated with plant closings initiated by Pfizer's manufacturing division.

For additional information regarding restructuring charges and acquisition-related costs, see Notes to Condensed Consolidated and Combined Financial Statements—Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Restructuring charges and certain acquisition-related costs decreased by \$3 million, or 50% in the third quarter of 2013 compared to the third quarter of 2012 due to the nonrecurrence of allocated charges from Pfizer.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Restructuring charges and certain acquisition-related costs decreased by \$65 million, in the first nine months of 2013 compared to the first nine months of 2012, primarily as a result of a \$27 million decrease in employee termination expenses related to the reversal of a previously established termination reserve related to our operations in Europe, and the nonrecurrence of allocated charges from Pfizer.

The aforementioned termination reserve was established when we were a business unit of Pfizer. As a result of becoming a standalone public company (no longer being a majority-owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve.

We continuously evaluate the viability of existing manufacturing, research, sourcing, and other efforts to ensure that we are operating as efficiently as possible. As a result, we expect to record restructuring and other charges as we exit facilities and continue to refine our cost structure. Subsequent to September 29, 2013 we have approved such actions that could amount to approximately \$20 million, but may have additional charges as events and circumstances change.

Interest expense, net of capitalized interest

| | Three Months Ended | | | Nine Months Ended | | |
|---|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Interest expense, net of capitalized interest | \$29 | \$7 | * | \$83 | \$23 | * |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Interest expense, net of capitalized interest, increased by \$22 million in the third quarter of 2013 compared to the third quarter of 2012, primarily due to the issuance of our senior notes on January 28, 2013. Interest expense related to allocated debt was \$7 million for the three months ended September 30, 2012. Interest expense related to our senior notes offering in January 2013, including amortization of debt discount and fees, was \$29 million for the three months ended September 29, 2013.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Interest expense, net of capitalized interest, increased by \$60 million in the first nine months of 2013 compared to the first nine months of 2012, primarily due to the issuance of our senior notes on January 28, 2013. Interest expense related to allocated debt was \$2 million and \$23 million for the nine months ended September 29, 2013 and September 30, 2012, respectively. Interest expense related to our senior notes offering in January 2013, including amortization of debt discount and fees, was \$81 million in first nine months of 2013.

Other (income)/deductions—net

| | Three Months Ended | | | Nine Months Ended | | |
|-------------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Other (income)/deductions—net | \$(6) | \$(11) | (45)% | \$(11) | \$(37) | (70)% |

Certain amounts and percentages may reflect rounding adjustments.

Edgar Filing: Zoetis Inc. - Form 10-Q

Three months ended September 29, 2013 vs. three months ended September 30, 2012

The change in Other (income)/deductions—net reflects an unfavorable impact of \$5 million on income attributable to Zoetis in the third quarter of 2013 compared to the third quarter of 2012. Included in Other (income)/deductions—net for the third quarter of 2013 is royalty income of \$8 million and a litigation-related charge of \$1 million. Included in Other (income)/deductions—net for the third quarter of 2012 is royalty income of \$11 million and foreign currency losses of \$1 million.

361

Table of Contents

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

The change in Other (income)/deductions—net reflects an unfavorable impact of \$26 million on income attributable to Zoetis in the first nine months of 2013 compared to the first nine months of 2012, primarily as a result of:

the nonrecurrence of income from a favorable legal settlement related to an intellectual property matter of \$14 million and a change in estimate for an environmental-related reserve due to a favorable settlement of \$7 million in 2012; and foreign currency loss of \$9 million related to the Venezuela currency devaluation in February 2013;

partially offset by:

a net gain of \$6 million on asset disposals associated with government-mandated divestitures; and

lower asset impairment charges of identifiable intangible assets of approximately \$4 million.

Provision for taxes on income

| | Three Months Ended | | | Nine Months Ended | | |
|-------------------------------|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| (MILLIONS OF DOLLARS) | | | | | | |
| Provision for taxes on income | \$54 | \$52 | 4% | \$165 | \$190 | (13)% |
| Effective tax rate | 29.2% | 24.4% | | 29.3% | 29.9% | |

Certain amounts and percentages may reflect rounding adjustments.

The effective tax rate was 29.2% for the third quarter of 2013, compared to 24.4% for the third quarter of 2012. The higher effective tax rate for the third quarter of 2013 compared to the third quarter of 2012 was primarily attributable to:

a \$29 million tax benefit during the third quarter of 2012 resulting from Pfizer's settlement with the U.S. Internal Revenue Service (IRS) with respect to the audits of the Pfizer Inc. tax returns for the years 2006 through 2008;

partially offset by:

incentive tax rulings in Belgium, effective December 1, 2012, and Singapore, effective October 29, 2012; and

changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs.

The effective tax rate was 29.3% for the first nine months of 2013, compared to 29.9% for the first nine months of 2012. The lower effective tax rate in the first nine months of 2013 compared to the first nine months of 2012 was primarily attributable to:

the aforementioned incentive tax rulings and changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs; and

a \$2 million discrete income tax benefit during the first quarter of 2013 related to the 2012 U.S. research and development tax credit which was retroactively extended on January 3, 2013;

partially offset by:

the tax benefit resulting from the aforementioned \$29 million IRS settlement in 2012.

Operating Segment Results

We believe that it is important to not only understand overall revenue and earnings growth, but also “operational growth.” Operational growth is defined as revenue or earnings growth excluding the impact of foreign exchange. On a global basis, the mix of our revenue between livestock and companion animal products are as follows:

| (MILLIONS OF DOLLARS) | Three Months Ended | | % Change | | |
|-----------------------|--------------------------|--------------------------|----------|--|------|
| | September 29, 2013 | September 30, 2012 | Total | Related to Foreign Exchange Operational | |
| U.S. | | | | | |
| Livestock | \$275 | \$248 | 11 | — | 11 |
| Companion animal | 220 | 200 | 10 | — | 10 |
| | 495 | 448 | 10 | — | 10 |
| EuAfME | | | | | |
| Livestock | 178 | 163 | 9 | 2 | 7 |
| Companion animal | 92 | 78 | 18 | 3 | 15 |
| | 270 | 241 | 12 | 3 | 9 |
| CLAR | | | | | |
| Livestock | 129 | 128 | 1 | (5 |) 6 |
| Companion animal | 42 | 37 | 14 | (5 |) 19 |
| | 171 | 165 | 4 | (5 |) 9 |
| APAC | | | | | |
| Livestock | 124 | 120 | 3 | (5 |) 8 |
| Companion animal | 43 | 45 | (4 |) (7 |) 3 |
| | 167 | 165 | 1 | (6 |) 7 |
| Total | | | | | |
| Livestock | 706 | 659 | 7 | (1 |) 8 |
| Companion animal | 397 | 360 | 10 | (1 |) 11 |
| | \$1,103 | \$1,019 | 8 | (1 |) 9 |

Certain amounts and percentages may reflect rounding adjustments.

Edgar Filing: Zoetis Inc. - Form 10-Q

| (MILLIONS OF DOLLARS) | Nine Months Ended | | % Change Total | Related to | |
|-----------------------|--------------------------|--------------------------|-------------------|---------------------|-------------|
| | September 29, 2013 | September 30, 2012 | | Foreign Exchange | Operational |
| U.S. | | | | | |
| Livestock | \$724 | \$680 | 6 | — | 6 |
| Companion animal | 662 | 614 | 8 | — | 8 |
| | 1,386 | 1,294 | 7 | — | 7 |
| EuAfME | | | | | |
| Livestock | 557 | 543 | 3 | 1 | 2 |
| Companion animal | 281 | 256 | 10 | 2 | 8 |
| | 838 | 799 | 5 | 1 | 4 |
| CLAR | | | | | |
| Livestock | 421 | 420 | — | (5 |) 5 |
| Companion animal | 134 | 129 | 4 | (3 |) 7 |
| | 555 | 549 | 1 | (5 |) 6 |
| APAC | | | | | |
| Livestock | 380 | 372 | 2 | (3 |) 5 |
| Companion animal | 148 | 146 | 1 | (6 |) 7 |
| | 528 | 518 | 2 | (3 |) 5 |
| Total | | | | | |
| Livestock | 2,082 | 2,015 | 3 | (2 |) 5 |
| Companion animal | 1,225 | 1,145 | 7 | (1 |) 8 |
| | \$3,307 | \$3,160 | 5 | (1 |) 6 |

Certain amounts and percentages may reflect rounding adjustments.

Edgar Filing: Zoetis Inc. - Form 10-Q

Earnings information by segment and the operational and foreign exchange changes versus the comparable prior year period are as follows:

| (MILLIONS OF DOLLARS) | Three Months Ended | | % Change Total | Related to | |
|---------------------------------|--------------------------|--------------------------|-------------------|------------|-------------|
| | September 29, 2013 | September 30, 2012 | | Exchange | Operational |
| U.S. | \$285 | \$232 | 23 | — | 23 |
| EuAfME | 92 | 91 | 1 | — | 1 |
| CLAR | 56 | 53 | 6 | (18 |) 24 |
| APAC | 57 | 59 | (3 |) (6 |) 3 |
| Total reportable segments | 490 | 435 | 13 | (3 |) 16 |
| Other business activities | (80 |) (65 |) 23 | | |
| Reconciling Items: | | | | | |
| Corporate | (139 |) (113 |) 23 | | |
| Purchase accounting adjustments | (12 |) (13 |) (8 |) | |
| Acquisition-related costs | (1 |) (5 |) (80 |) | |
| Certain significant items | (46 |) (11 |) * | | |
| Other unallocated | (27 |) (15 |) 80 | | |
| Income before income taxes | \$185 | \$213 | (13 |) | |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

| (MILLIONS OF DOLLARS) | Nine Months Ended | | % Change Total | Related to | |
|---------------------------------|--------------------------|--------------------------|-------------------|------------|-------------|
| | September 29, 2013 | September 30, 2012 | | Exchange | Operational |
| U.S. | \$773 | \$676 | 14 | — | 14 |
| EuAfME | 300 | 283 | 6 | — | 6 |
| CLAR | 186 | 184 | 1 | (11 |) 12 |
| APAC | 203 | 193 | 5 | (2 |) 7 |
| Total reportable segments | 1,462 | 1,336 | 9 | (2 |) 11 |
| Other business activities | (228 |) (191 |) 19 | | |
| Reconciling Items: | | | | | |
| Corporate | (392 |) (346 |) 13 | | |
| Purchase accounting adjustments | (37 |) (39 |) (5 |) | |
| Acquisition-related costs | (17 |) (34 |) (50 |) | |
| Certain significant items | (130 |) (28 |) * | | |
| Other unallocated | (94 |) (62 |) 52 | | |
| Income before income taxes | \$564 | \$636 | (11 |) | |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

U.S. operating segment

U.S. segment revenue increased by \$47 million, or 10%, in the third quarter of 2013 compared to the third quarter of 2012, of which approximately \$27 million resulted from growth in livestock products and approximately \$20 million resulted from growth in companion animal products.

- Livestock revenue growth was achieved in all species, particularly cattle. Strong growth in sales of cattle products was primarily due to an unusually weak year-ago quarter as a result of last year's drought. The growth

in sales of poultry products was due to growth in medicated feed additives and the growth in swine products was due to continued customer acceptance of new products and the successful execution of marketing programs developed for and focused on specific brands, therapeutic categories or customer segments. Results also reflect the benefit of price increases taken in the first quarter.

Companion animal revenue growth was driven by solid growth in small animal products reflecting the benefit of price increases taken in the first quarter, strong market dynamics, the positive impact of increased field force optimization efforts, and uptake in customer loyalty and other promotional programs. Growth was tempered by relatively flat equine sales.

U.S. segment earnings increased by \$53 million, or 23%, in the third quarter of 2013 compared to the third quarter of 2012 due to strong revenue growth, favorable product mix and the timing of certain promotional spending.

EuAfME operating segment

EuAfME segment revenue increased by \$29 million, or 12%, in the third quarter of 2013 compared to the third quarter of 2012. Operational revenue growth was \$23 million, or 9%, of which approximately \$12 million resulted from growth in companion animal products and approximately \$11 million resulted from growth in livestock products.

Livestock revenue growth was primarily driven by emerging markets, particularly Russia, South Africa, Turkey and Algeria. Growth in Russia and South Africa was primarily due to the launch of new products in these markets.

Additionally, growth in swine was favorably impacted by the launch of a new swine vaccine (that prevents porcine circovirus type 2) across many markets in the region. This growth was partially offset by continuing challenging market conditions throughout Western Europe affecting the cattle portfolio, as well as product supply issues affecting the poultry portfolio in emerging markets.

Companion animal revenue growth was favorably impacted by increased sales of products that are related to certain third party manufacturing agreements. Growth in the third quarter of 2013 also benefited from the late start of the parasiticide season, which delayed the timing of sales versus the year-ago quarter.

Additionally, segment revenue was favorably impacted by foreign exchange, which increased revenue by approximately \$6 million, or 3%.

EuAfME segment earnings increased by \$1 million, or 1%, in the third quarter of 2013 compared to the third quarter of 2012, as the benefit of increased revenue was offset by unfavorable geographic and product mix.

CLAR operating segment

CLAR segment revenue increased by \$6 million, or 4%, in the third quarter of 2013 compared to the third quarter of 2012. Operational revenue growth was \$14 million, or 9%, of which approximately \$7 million resulted from growth in livestock products and \$7 million resulted from growth in companion animal product sales.

Livestock revenue growth was primarily driven by increased sales in the cattle and poultry portfolios. Growth in cattle was primarily due to growth in Venezuela, Canada and Mexico. Growth in sales of poultry products was primarily driven by higher sales of medicated feed additives in Brazil. This growth was partially offset by challenging market conditions affecting the cattle market in Brazil, where sales were relatively flat primarily due to increased local competition and drought conditions in certain areas of the country.

Companion animal growth was favorably impacted by increased sales in Canada driven primarily by timing of the parasiticide season and price increases. In addition, revenue was favorably impacted by an increasing companion animal market in Brazil.

Additionally, segment revenue was unfavorably impacted by foreign exchange, which decreased revenue by approximately \$8 million, or 5%.

CLAR segment earnings increased by \$3 million, or 6%, in the third quarter of 2013 compared to the third quarter of 2012. Operational earnings growth was \$13 million, or 24%, in the third quarter of 2013 compared to the third quarter of 2012, primarily driven by revenue growth and favorable product mix.

APAC operating segment

APAC segment revenue increased by \$2 million, or 1%, in the third quarter of 2013 compared to the third quarter of 2012. Operational revenue growth was \$11 million, or 7%, of which approximately \$10 million resulted from growth in livestock products and approximately \$1 million resulted from growth in companion animal products.

Livestock revenue growth was driven primarily by increased sales in emerging markets across swine, poultry and cattle. Growth in sales of swine products was driven by higher demand and market penetration in China. Growth in the poultry portfolio was driven by higher sales in India as a result of the resolution of a license registration issue and higher demand in other emerging markets. Cattle product sales growth was primarily driven by increased sales in New Zealand and was partially offset by declining cattle sales in Australia due to the impact of prolonged drought conditions on herd sizes.

Companion animal revenue growth was primarily due to increased sales in Taiwan as a result of a rabies outbreak, the successful launch of a new product in Japan, and the resolution of a supply issue and focused field force initiatives in China. This was partially offset by declines in Australia due to increased competition.

Additionally, segment revenue was unfavorably impacted by foreign exchange, which decreased revenue by approximately \$9 million, or 6%.

APAC segment earnings decreased by \$2 million, or 3%, in the third quarter of 2013 compared to the third quarter of 2012. Operational earnings growth was \$2 million, or 3%, in the third quarter of 2013 compared to the third quarter of 2012, primarily due to increased revenue, partially offset by the unfavorable impact of geographic and product mix and increased investment in promotional activities.

41 |

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

U.S. operating segment

U.S. segment revenue increased by \$92 million, or 7%, in the first nine months of 2013 compared to the first nine months of 2012, of which approximately \$44 million resulted from growth in livestock products and approximately \$48 million resulted from growth in companion animal products.

Livestock revenue growth was achieved across poultry, cattle and swine products due to the positive impact of increased field force optimization efforts and a new portfolio pricing structure implemented late in 2012.

Companion animal revenue growth was driven by solid growth in small animal products reflecting strong promotional support and price increases. Results were partially offset by a decrease in equine sales reflecting the continuing contraction of the market.

U.S. segment earnings increased by \$97 million, or 14%, in the first nine months of 2013 compared to the first nine months of 2012, as a result of strong revenue growth and favorable product mix.

EuAfME operating segment

EuAfME segment revenue increased by \$39 million, or 5%, in the first nine months of 2013 compared to the first nine months of 2012. Operational revenue growth was \$35 million, or 4%, of which approximately \$13 million resulted from growth in livestock products and approximately \$22 million resulted from growth in companion animal products.

Livestock revenue growth was driven primarily by growth in the swine portfolio as a result of the launch of a new swine vaccine (that prevents porcine circovirus type 2) across many markets in the region. Results were partially offset by continuing adverse macroeconomic conditions throughout Western Europe affecting the cattle portfolio.

Companion animal revenue growth was favorably impacted by increased sales of products that are related to certain third party manufacturing agreements. Additionally, sales in France increased largely due to the unfavorable impact in the prior year of initial guidance on the usage of anti-infective products and the benefit of increased promotional programs. Results were partially offset by continued adverse macroeconomic conditions throughout Western Europe. Additionally, segment revenue was favorably impacted by foreign exchange, which increased revenue by approximately \$4 million.

EuAfME segment earnings increased by \$17 million, or 6%, in the first nine months of 2013 compared to the first nine months of 2012, primarily due to higher revenue and increased operating efficiencies.

CLAR operating segment

CLAR segment revenue increased by \$6 million, or 1% in the first nine months of 2013 compared to the first nine months of 2012. Operational revenue growth was \$31 million, or 6%, of which approximately \$22 million resulted from growth in livestock products, and approximately \$9 million resulted from growth in companion animal product sales.

Livestock revenue was favorably impacted by growth in poultry and swine products in Brazil. Growth in poultry revenue was driven by increased sales of medicated feed additives. Swine vaccines benefited from continued demand in South America across several product lines, including Improvac/Improvast, a product that reduces boar taint without the need for surgical castration. Cattle revenue in Canada benefited from a strong fall calf season in the first quarter of 2013, while revenue in other countries was negatively impacted by a decline in cattle growth related to increased local competition and challenging market conditions as a result of drought conditions.

Companion animal revenue was favorably impacted by an increasing companion animal market in Brazil and marketing programs in Brazil and Mexico. Gains were partially offset by the equine business as a result of a reduced number of horses in Canada. Revenue also declined slightly due to the favorable impact in the prior year of a competitor supply issue in Canada.

Additionally, segment revenue was unfavorably impacted by foreign exchange, which decreased revenue by approximately \$25 million, or 5%.

CLAR segment earnings increased by \$2 million, or 1% in the first nine months of 2013 compared to the first nine months of 2012. Operational earnings growth was \$23 million, or 12%, in the first nine months of 2013 compared to the first nine months of 2012. The increase was driven by improvements in product mix. This performance was offset by the continued impact of the Venezuela currency devaluation in February 2013, which unfavorably impacted

earnings by \$14 million.

APAC operating segment

APAC segment revenue increased by \$10 million, or 2%, in the first nine months of 2013 compared to the first nine months of 2012. Operational revenue growth was \$27 million, or 5%, of which approximately \$17 million resulted from growth in livestock products and approximately \$10 million resulted from growth in companion animal products.

Livestock revenue growth was driven primarily by increased sales of swine products, particularly in our porcine circovirus type 2 vaccine, which was recently launched in several new markets in Southeast Asia, Taiwan and Korea. Positive growth in swine products was tempered by challenging market conditions for pork producers in Southeast and Northeast Asia, with some impact in China. Growth in the poultry portfolio, particularly in Southeast Asia, also positively contributed to livestock performance, despite

42 |

challenging market conditions in China. These increases were partially offset by declining cattle sales in Australia due to the impact of the prolonged drought conditions on herd sizes.

Companion animal revenue growth was primarily due to the successful launch of a new product in Japan, as well as the successful execution of marketing programs developed for and focused on specific brands, therapeutic categories or customer segments.

Additionally, segment revenue was unfavorably impacted by foreign exchange, which decreased revenue by approximately \$17 million, or 3%.

APAC segment earnings increased by \$10 million, or 5%, in the first nine months of 2013 compared to the first nine months of 2012. Operational earnings growth was \$14 million, or 7%, in the first nine months of 2013 compared to the first nine months of 2012 driven by revenue growth.

Other business activities

Reflects the R&D activity managed by our centralized Research and Development Organization.

Three months ended September 29, 2013 vs. three months ended September 30, 2012

Our centralized spending on R&D increased by \$15 million, or 23%, in the third quarter of 2013 compared to the third quarter of 2012, primarily due to \$12 million in comparable R&D expense for the third quarter of 2012 included in the Corporate segment related to operations now managed by the Research and Development Organization.

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Our centralized spending on R&D increased by \$37 million, or 19%, in the first nine months of 2013 compared to the first nine months of 2012, primarily due to \$30 million in comparable R&D expense for the first nine months of 2012 included in the Corporate segment related to operations now managed by the Research and Development Organization.

Reconciling items

See Notes to Condensed Consolidated and Combined Financial Statements—Note 16. Segment and Other Revenue Information for more information.

Adjusted net income

General description of adjusted net income (a non-GAAP financial measure)

Adjusted net income is an alternative view of performance used by management, and we believe that investors' understanding of our performance is enhanced by disclosing this performance measure. We report adjusted net income to portray the results of our major operations, the discovery, development, manufacture and commercialization of animal health medicine and vaccine products, prior to considering certain income statement elements. We have defined adjusted net income as net income attributable to Zoetis before the impact of purchase accounting adjustments, acquisition-related costs and certain significant items. The adjusted net income measure is not, and should not be viewed as, a substitute for U.S. GAAP reported net income attributable to Zoetis.

The adjusted net income measure is an important internal measurement for us. We measure our overall performance on this basis in conjunction with other performance metrics. The following are examples of how the adjusted net income measure is utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an adjusted net income basis;

- our annual budgets are prepared on an adjusted net income basis; and

- other goal setting and performance measurements.

Despite the importance of this measure to management in goal setting and performance measurement, adjusted net income is a non-GAAP financial measure that has no standardized meaning prescribed by U.S. GAAP and, therefore, has limits in its usefulness to investors. Because of its non-standardized definition, adjusted net income, unlike U.S. GAAP net income, may not be comparable to the calculation of similar measures of other companies. Adjusted net income is presented to permit investors to more fully understand how management assesses performance.

We also recognize that, as an internal measure of performance, the adjusted net income measure has limitations, and we do not restrict our performance management process solely to this metric. A limitation of the adjusted net income measure is that it provides a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and does not provide a comparable view of our performance

to other companies. We also use other specifically tailored tools designed to achieve the highest levels of performance.

43 |

Table of Contents

Purchase accounting adjustments

Adjusted net income is calculated prior to considering certain significant purchase accounting impacts that result from business combinations and net asset acquisitions. These impacts, primarily associated with the Pharmacia Animal Health business (acquired in 2003), Fort Dodge Animal Health (FDAH) (acquired in 2009) and King Animal Health (KAH) (acquired in 2011), include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets and depreciation related to the increase/decrease to fair value of the acquired fixed assets. Therefore, the adjusted net income measure includes the revenue earned upon the sale of the acquired products without considering the aforementioned significant charges.

While certain purchase accounting adjustments can occur through 20 or more years, this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by providing a degree of parity to internally developed intangible assets for which R&D costs previously have been expensed.

A completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through adjusted net income. These components of adjusted net income are derived solely from the impact of the items listed above. We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting revenue, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our adjusted net income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.

Acquisition-related costs

Adjusted net income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with significant business combinations or net-asset acquisitions because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate certain businesses as a result of the acquisition decision. We have made no adjustments for the resulting synergies.

We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in a business combination result primarily from the need to eliminate duplicate assets, activities or employees—a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in the ordinary course of business.

The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the regulated nature of the animal health medicines and vaccines business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the Food and Drug Administration and/or other regulatory authorities.

Certain significant items

Adjusted net income is calculated prior to considering certain significant items. Certain significant items represent substantive, unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspect of their unusual nature. Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be costs related to becoming a standalone public company, a major non-acquisition-related restructuring charge and associated

implementation costs for a program that is specific in nature with a defined term, such as those related to our non-acquisition-related cost-reduction and productivity initiatives; amounts related to disposals of products or facilities that do not qualify as discontinued operations as defined by U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation; or charges related to legal matters. See Notes to Condensed Consolidated and Combined Financial Statements—Note 15. Commitments and Contingencies. Our normal, ongoing defense costs or settlements of and accruals on legal matters made in the normal course of our business would not be considered certain significant items.

Table of Contents

Reconciliation

A reconciliation of net income attributable to Zoetis, as reported under U.S. GAAP, to adjusted net income follows:

| (MILLIONS OF DOLLARS) | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| Reported net income attributable to Zoetis | \$ 131 | \$ 162 | (19) | \$ 399 | \$ 446 | (11) |
| Purchase accounting adjustments—net of tax | 8 | 9 | (11) | 25 | 26 | (4) |
| Acquisition-related costs—net of tax | — | 4 | (100) | 11 | 23 | (52) |
| Certain significant items—net of tax | 33 | (21) | * | 94 | (13) | * |
| Adjusted net income ^(a) | \$ 172 | \$ 154 | 12 | \$ 529 | \$ 482 | 10 |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

The effective tax rate on adjusted pretax income is 29.5% and 36.8% for the third quarter of 2013 and 2012, respectively, and 29.3% and 34.6% for the first nine months of 2013 and 2012, respectively. The lower effective tax rate in 2013 compared to 2012 is due to incentive tax rulings in Belgium, effective December 1, 2012, and

^(a) Singapore, effective October 29, 2012, as well as changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs. In addition, we recognized a \$2 million discrete income tax provision benefit during the first quarter of 2013 related to the 2012 U.S. research and development tax credit which was retroactively extended on January 3, 2013.

The following table provides a reconciliation of reported diluted earnings per share (EPS), as reported under U.S. GAAP, and non-GAAP adjusted diluted EPS:

| Earnings per share—diluted ^{(a)(b)} : | Three Months Ended | | | Nine Months Ended | | |
|---|--------------------------|--------------------------|-------------|--------------------------|--------------------------|-------------|
| | September 29, 2013 | September 30, 2012 | % Change | September 29, 2013 | September 30, 2012 | % Change |
| GAAP Reported net income attributable to Zoetis | \$ 0.26 | \$ 0.32 | (19) | \$ 0.80 | \$ 0.89 | (10) |
| Purchase accounting adjustments—net of tax | 0.02 | 0.02 | — | 0.05 | 0.05 | — |
| Acquisition-related costs—net of tax | — | 0.01 | (100) | 0.02 | 0.05 | (60) |
| Certain significant items—net of tax | 0.06 | (0.04) | * | 0.19 | (0.03) | * |
| Non-GAAP adjusted net income | \$ 0.34 | \$ 0.31 | 10 | \$ 1.06 | \$ 0.96 | 10 |

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

The weighted-average shares outstanding for diluted earnings per share for the period prior to the IPO was calculated using an aggregate of 500 million shares of Class A and Class B common stock outstanding, which was

^(a) the number of Zoetis Inc. shares outstanding immediately prior to the IPO. For the three and nine months ended September 29, 2013, diluted earnings per share was computed using the weighted-average common shares outstanding during the period plus the common stock equivalents related to stock options, RSUs and DSUs.

^(b) EPS amounts may not add due to rounding.

Adjusted net income includes the following charges for each of the periods presented:

| (MILLIONS OF DOLLARS) | Three Months Ended | | Nine Months Ended | |
|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| | | | | |

Edgar Filing: Zoetis Inc. - Form 10-Q

| | | | | |
|--------------|------|-----|------|------|
| Interest | \$29 | \$7 | \$83 | \$23 |
| Taxes | 72 | 89 | 219 | 255 |
| Depreciation | 32 | 41 | 100 | 93 |
| Amortization | 5 | 4 | 13 | 14 |

45 |

Table of Contents

Adjusted net income, as shown above, excludes the following items:

| (MILLIONS OF DOLLARS) | Three Months Ended | | Nine Months Ended | |
|---|--------------------------|--------------------------|--------------------------|--------------------------|
| | September 29, 2013 | September 30, 2012 | September 29, 2013 | September 30, 2012 |
| Purchase accounting adjustments: | | | | |
| Amortization and depreciation ^(a) | \$ 12 | \$ 12 | \$ 35 | \$ 36 |
| Cost of sales ^(b) | — | 1 | 2 | 3 |
| Total purchase accounting adjustments—pre-tax | 12 | 13 | 37 | 39 |
| Income taxes ^(c) | 4 | 4 | 12 | 13 |
| Total purchase accounting adjustments—net of tax | 8 | 9 | 25 | 26 |
| Acquisition-related costs ^(d) : | | | | |
| Integration costs ^(e) | 1 | 10 | 16 | 31 |
| Restructuring costs ^(f) | — | (11 |) 1 | (8 |
| Additional depreciation—asset restructuring ^(g) | — | 6 | — | 11 |
| Total acquisition-related costs—pre-tax | 1 | 5 | 17 | 34 |
| Income taxes ^(c) | 1 | 1 | 6 | 11 |
| Total acquisition-related costs—net of tax | — | 4 | 11 | 23 |
| Certain significant items ^(h) : | | | | |
| Restructuring charges ⁽ⁱ⁾ | — | 7 | (27 |) 32 |
| Implementation costs and additional depreciation—asset restructuring ^(g) | — | 3 | 3 | 14 |
| Certain asset impairment charges ^(j) | — | — | 1 | — |
| Net gains on sale of assets ^(k) | — | — | (6 |) — |
| Stand-up costs ^(l) | 41 | — | 152 | — |
| Other ^(m) | 5 | 1 | 7 | (18 |
| Total significant items—pre-tax | 46 | 11 | 130 | 28 |
| Income taxes ^(c) | 13 | 32 | 36 | 41 |
| Total significant items—net of tax | 33 | (21 |) 94 | (13 |
| Total purchase accounting adjustments, acquisition-related costs, and certain significant items—net of tax | \$ 41 | \$ (8 |) \$ 130 | \$ 36 |

Certain amounts may reflect rounding adjustments.

Amortization and depreciation expense related to purchase accounting adjustments with respect to identifiable intangible assets and property, plant and equipment were distributed as follows: \$11 million and \$34 million in the three and nine months ended September 29, 2013, respectively, and \$12 million and \$37 million in the three and nine months ended September 30, 2012, respectively, included in Amortization of intangible assets; \$1 million income in the nine months ended September 30, 2012, included in Selling, general and administrative expenses; and \$1 million in both the three and nine months ended September 29, 2013, respectively, included in Research and development expenses.

(a) Depreciation expense included in Cost of sales.

(b) Included in Provision for taxes on income.

Acquisition-related costs were distributed as follows: \$2 million income in the three months ended September 29, 2013 and \$4 million and \$9 million in the three and nine months ended September 30, 2012, respectively, included in Cost of sales; \$2 million in both the three and nine months ended September 30, 2012 included in Selling, general and administrative expenses; \$3 million and \$17 million in the three and nine months ended September 29, 2013, respectively, and \$1 million income and \$23 million in the three and nine months ended September 30, 2012, respectively, included in Restructuring charges and certain acquisition-related costs.

(c)

Integration costs were distributed as follows: \$2 million income in the three months ended September 29, 2013 included in Cost of sales, and \$3 million and \$16 million in the three and nine months ended September 29, 2013, respectively, and \$10 million and \$31 million in the three and nine months ended September 30, 2012, respectively, included in Restructuring charges and certain acquisition-related costs.

Included in Restructuring charges and certain acquisition-related costs. See Notes to Condensed Consolidated and (f) Combined Financial Statements—Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Amounts primarily relate to our cost-reduction/productivity initiatives. See Notes to Condensed Consolidated and (g) Combined Financial Statements—Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

Certain significant items were distributed as follows: \$4 million and \$20 million in the three and nine months ended September 29, 2013, respectively, and \$2 million and \$4 million income in the three and nine months ended September 30, 2012, respectively, included in Cost of sales; \$40 million and \$135 million in the three and nine months ended September 29, 2013, respectively, and \$3 million and \$4 million in the three and nine months ended September 30, 2012, respectively, included in Selling, general and administrative expenses; \$1 million and \$5 (h) million in the three and nine months ended September 29, 2013, respectively, and \$10 million in the nine months ended September 30, 2012, included in Research and development expenses; \$26 million income in the nine months ended September 29, 2013 and \$7 million and \$32 million in the three and nine months ended September 30, 2012, respectively, included in Restructuring charges and certain acquisition-related costs; and \$1 million and \$3 million income in the three and nine months ended September 29, 2013, respectively, and \$1 million income and \$14 million income in the three and nine months ended September 30, 2012, included in Other (Income)/Deductions—Net.

Table of Contents

- Represents restructuring charges incurred for our cost-reduction/productivity initiatives. Included in Restructuring charges and certain acquisition-related costs. See Notes to Condensed Consolidated and Combined Financial Statements—Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
- (i) Included in Other (income)/deductions—net. See Notes to Condensed Consolidated and Combined Financial Statements—Note 6. Other (Income)/Deductions—Net for more information.
- (k) Represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009. Included in Other (income)/deductions—net. See Notes to Condensed Consolidated and Combined Financial Statements—Note 6. Other (Income)/Deductions—Net for more information.
- (l) Certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, accelerated vesting and associated cash payment related to certain Pfizer equity awards, and certain legal registration and patent assignment costs which were distributed as follows: \$3 million and \$18 million in the three and nine months ended September 29, 2013, respectively, included in Cost of sales; \$38 million and \$129 million in the three and nine months ended September 29, 2013, respectively, included in Selling, general and administrative expenses, and \$5 million in the nine months ended September 29, 2013 included in Research and development expenses.
- (m) For the three and nine months ended September 29, 2013, primarily relates to litigation-related charges (\$5 million) and charges related to transitional manufacturing purchase agreements associated with divestitures (\$1 million). For the nine months ended September 30, 2012, primarily relates to income related to a favorable legal settlement for an intellectual property matter (\$14 million) and income due to a change in estimate related to transitional manufacturing purchase agreements associated with divestitures (\$4 million).

Our financial guidance for 2013

Our 2013 financial guidance is summarized below:

Selected Line Items

| | |
|--|-----------------------------------|
| Revenue | \$4,475 to \$4,525 million |
| Adjusted cost of sales as a percentage of revenue ^(a) | Approximately 35.5% |
| Adjusted SG&A expenses ^(a) | \$1,405 to \$1,425 million |
| Adjusted R&D expenses ^(a) | \$380 to \$390 million |
| Adjusted interest expense ^(a) | Approximately \$115 million |
| Adjusted other (income)/deductions ^(a) | Approximately \$15 million income |
| Effective tax rate on adjusted net income ^(a) | Approximately 29.5% |
| Adjusted diluted EPS ^(a) | \$1.38 to \$1.42 |
| Certain significant items ^(b) and acquisition-related costs | \$220 to \$240 million |
| Reported diluted EPS | \$0.98 to \$1.02 |

(a) For an understanding of adjusted net income and its components, see the “Adjusted net income” section of this MD&A.

(b) Includes certain nonrecurring costs related to becoming a standalone public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation and certain legal registration and patent assignment costs.

In updating our guidance for full-year 2013, we have considered current exchange rates and other factors.

A reconciliation of 2013 adjusted net income and adjusted diluted EPS guidance to 2013 reported net income attributable to Zoetis and reported diluted EPS attributable to Zoetis common shareholders guidance follows:

| (MILLION OF DOLLARS, EXCEPT PER SHARE AMOUNTS) | Full-Year 2013 Guidance | |
|---|-------------------------|------------------|
| | Net Income | Diluted EPS |
| Adjusted net income/diluted EPS ^(a) guidance | ~\$690 - \$710 | ~\$1.38 - \$1.42 |
| Purchase accounting adjustments | ~(35) | ~(0.07) |

Edgar Filing: Zoetis Inc. - Form 10-Q

| | | |
|--|----------------|------------------|
| Certain significant items ^(b) and acquisition-related costs | (160 - 175) | (0.32 - 0.35) |
| Reported net income attributable to Zoetis Inc./diluted EPS guidance | ~\$490 - \$510 | ~\$0.98 - \$1.02 |

(a) For an understanding of adjusted net income, see the “Adjusted net income” section of this MD&A.

Includes certain nonrecurring costs related to becoming a standalone public company, such as new branding

(b) (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation and certain legal registration and patent assignment costs.

Our 2013 financial guidance is subject to a number of factors and uncertainties—as described in the “Forward-looking information and factors that may affect future results,” “Our operating environment” and “Our strategy” and in Part I, Item 1A. “Risk Factors” of our 2012 Annual Report on Form 10-K.

Analysis of the condensed consolidated and combined statements of comprehensive income

Virtually all changes in other comprehensive income for the periods presented are related to foreign currency translation adjustments. These changes result from the strengthening or weakening of the U.S. dollar as compared to the currencies in the countries in which we do business. The gains and losses associated with these changes are deferred on the balance sheet in Accumulated other comprehensive loss until realized.

Table of Contents

Analysis of the condensed consolidated and combined balance sheets

September 29, 2013 vs. December 31, 2012

For a discussion about the changes in Cash and cash equivalents, Short-term borrowing, including current portion of allocated long term debt, and Long-term debt, see “Analysis of financial condition, liquidity and capital resources” below.

Accounts receivable, less allowance for doubtful accounts increased as a result of operational increases due to higher net sales. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Inventories decreased primarily as a result of Separation Adjustments. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation and Note 10. Inventories.

The net changes in Current deferred tax assets, Noncurrent deferred tax assets, Noncurrent deferred tax liabilities and Other taxes payable primarily reflect Separation Adjustments. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation and Note 7. Income Taxes.

Property, plant and equipment, less accumulated depreciation increased slightly. Operational activity (depreciation and capital spending) was partially offset by Separation Adjustments. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Dividends payable relates to the dividend declared on September 12, 2013.

Accrued Compensation and related items declined primarily due to the payment of 2012 annual bonuses to eligible U.S.-based employees in the first half of 2013, partially offset by the accrual for cash payments to certain non-executive Zoetis employees associated with the forfeiture of Pfizer equity awards. See Notes to Condensed Consolidated and Combined Financial Statements— Note 13E. Share-Based Payments: Treatment of Outstanding Pfizer Equity Awards.

Long-term debt reflects the senior notes offering. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2C. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Senior Notes Offering and Note 9D. Financial Instruments: Senior Notes Offering.

Allocated long-term debt decreased as a result of Separation Adjustments. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

Other noncurrent liabilities increased as a result of Separation Adjustments. See Notes to Condensed Consolidated and Combined Financial Statements— Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.

For an analysis of the changes in Total Equity, see the Condensed Consolidated and Combined Statements of Equity.

Analysis of the condensed consolidated and combined statements of cash flows

| (MILLIONS OF DOLLARS) | Nine Months Ended | | | % Change | % Change |
|--|--------------------|--------------------|------|----------|----------|
| | September 29, 2013 | September 30, 2012 | | | |
| Net cash provided by (used in): | | | | | |
| Operating activities | \$383 | \$144 | * | | |
| Investing activities | (128) | (89) |) 44 | | % |
| Financing activities | (172) | — | * | | |
| Effect of exchange-rate changes on cash and cash equivalents | (11) | (1) |) * | | |

| | | | | |
|---|------|------|----|---|
| Net increase in cash and cash equivalents | \$72 | \$54 | 33 | % |
|---|------|------|----|---|

* Calculation not meaningful.

Certain amounts and percentages may reflect rounding adjustments.

Operating activities

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Our net cash provided by operating activities was \$383 million in the first nine months of 2013 compared to cash provided by operating activities of \$144 million in the first nine months of 2012. This increase in operating cash flows was primarily attributable to timing of receipts and payments in the ordinary course of business and operational reductions in inventory.

48 |

For the nine months ended September 30, 2012, the line item "Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc." primarily reflects the timing of production of certain products, which are produced only once a year.

Investing activities

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Our net cash used in investing activities was \$128 million in the first nine months of 2013 compared to cash used in investing activities of \$89 million in the first nine months of 2012 primarily due to increased capital investment.

Financing activities

Nine months ended September 29, 2013 vs. nine months ended September 30, 2012

Our net cash used in financing activities was \$172 million in the first nine months of 2013 compared to cash used in financing activities of less than \$1 million in the first nine months of 2012. The net cash used in financing activities for 2013 was attributable to the net transfers to Pfizer as a result of the Separation.

Analysis of financial condition, liquidity and capital resources

While we believe our cash and cash equivalents on hand, our operating cash flows and our existing financing arrangements will be sufficient to support our future cash needs, this may be subject to the environment in which we operate. Risks to our meeting future funding requirements include global economic conditions described in the following paragraph.

Over the last five years, the global financial markets have undergone and may continue to experience significant volatility and disruption. The timing and sustainability of an economic recovery is uncertain and additional macroeconomic, business and financial disruptions may arise. As markets change, we will continue to monitor our liquidity position, and there can be no assurance that the challenging economic environment or a further economic downturn would not impact our liquidity or our ability to obtain future financing.

Selected measures of liquidity and capital resources

Certain relevant measures of our liquidity and capital resources follow:

| | September 29, 2013 | December 31, 2012 |
|---|--------------------------|-------------------------|
| (MILLIONS OF DOLLARS) | | |
| Cash and cash equivalents ^(a) | \$389 | \$317 |
| Accounts receivable, net ^(b) | 1,110 | 900 |
| Short-term borrowings, including current portion of allocated long-term debt in 2012 ^(c) | 10 | 73 |
| Allocated long-term debt ^(c) | — | 509 |
| Long-term debt ^(d) | 3,642 | — |
| Working capital | 1,775 | 1,741 |
| Ratio of current assets to current liabilities | 2.36:1 | 2.55:1 |

Prior to our IPO, we participated in Pfizer's centralized cash management system, and generally all of our excess cash was transferred to Pfizer on a daily basis. Cash disbursements for operations and/or investing activities were funded, as needed, by Pfizer.

Accounts receivable are usually collected over a period of 60 to 90 days. For the nine months ended September 29, 2013 compared to December 31, 2012, the number of days that accounts receivable are outstanding remained approximately the same. We regularly monitor our accounts receivable for collectability, particularly in markets where economic conditions remain uncertain. We believe that our allowance for doubtful accounts is appropriate. Our assessment is based on such factors as past due history, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.

The combined financial statements for December 31, 2012 include an allocation of long-term debt from Pfizer that was issued to partially finance the acquisition of Wyeth (including FDAH). The debt has been allocated on a pro-rata basis using the deemed acquisition cost of FDAH as a percentage of the total acquisition cost of Wyeth. After the IPO, Pfizer retained the allocated debt.

Primarily consists of \$3.65 billion aggregate principal amount of our senior notes, with an original issue discount of \$10 million. The senior notes are comprised of \$400 million aggregate principal amount of our 1.150% senior

notes due 2016, \$750 million aggregate principal amount of our 1.875% senior notes due 2018, \$1.35 billion aggregate principal amount of our 3.250% Senior Notes due 2023 and \$1.15 billion aggregate principal amount of our 4.700% senior notes due 2043.

For additional information about the sources and uses of our funds, see the "Analysis of the condensed consolidated and combined balance sheets" and "Analysis of the condensed consolidated and combined statements of cash flows" sections of the MD&A.

Credit facility and other lines of credit

In December 2012, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year \$1.0 billion senior unsecured revolving credit facility, which became effective in February 2013 upon the completion of the IPO and which expires in December 2017. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 4.35:1 for fiscal year 2013, 3.95:1 for fiscal year 2014, 3.50:1 for fiscal year 2015 and 3.00:1 thereafter. The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to

Table of Contents

interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants. Subject to certain conditions, we have the right to increase the credit facility to up to \$1.5 billion. There are currently no borrowings outstanding.

We have additional lines of credit with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 29, 2013, we had access to \$125 million of lines of credit which expire at various times through 2016. As of September 29, 2013 we had \$10 million of short-term borrowings outstanding and \$2 million of long-term borrowings outstanding.

Domestic and international short-term funds

Many of our operations are conducted outside the U.S. As part of the Separation, we received significant portions of cash and cash equivalents held internationally. Approximately 60% of cash and cash equivalents transferred was held outside the U.S. Going forward, the amount of funds held in U.S. tax jurisdictions will fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). Repatriation of overseas funds can result in additional U.S. federal, state and local income tax payments. We record U.S. deferred tax liabilities for certain unremitted earnings, but when amounts earned overseas are expected to be indefinitely reinvested outside the U.S., no accrual for U.S. taxes is provided.

Debt

On January 28, 2013, we issued \$3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of \$10 million. The senior notes are comprised of \$400 million aggregate principal amount of our 1.150% senior notes due 2016, \$750 million aggregate principal amount of our 1.875% senior notes due 2018, \$1.35 billion aggregate principal amount of our 3.250% senior notes due 2023 and \$1.15 billion aggregate principal amount of our 4.700% senior notes due 2043.

We sold \$2.65 billion aggregate principal amount of our senior notes through the initial purchasers in the senior notes offering and Pfizer transferred \$1.0 billion aggregate principal amount of our senior notes to certain of the initial purchasers, who sold such senior notes through the initial purchasers in the senior notes offering. We paid an amount of cash equal to substantially all of the net proceeds that we received in the senior notes offering to Pfizer prior to the completion of the IPO.

The senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.

Pursuant to the indenture, we are able to redeem the senior notes of any series, in whole or in part, at any time by paying a "make whole" premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2023 notes pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.

In connection with the senior notes offering, we entered into a registration rights agreement (the Registration Rights Agreement) with the representatives of the initial purchasers of the senior notes. Pursuant to the terms of the Registration Rights Agreement, we were obligated, among other things, to use our commercially reasonable efforts to file a registration statement with the SEC enabling holders of the senior notes to exchange the privately placed notes for publicly registered notes with substantially the same terms. We filed the registration statement with the SEC on September 13, 2013, the SEC declared the registration statement effective on September 24, 2013, and the exchange offer was completed on October 31, 2013.

The components of our long-term debt follow:

| Description | Principal Amount | Interest Rate | Terms |
|------------------|------------------|---------------|--|
| Lines of credit | \$2 million | 6.400% | |
| 2016 Senior Note | \$400 million | 1.150% | Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2016 |
| 2018 Senior Note | \$750 million | 1.875% | Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2018 |
| 2023 Senior Note | \$1,350 million | 3.250% | Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2023 |
| 2043 Senior Note | \$1,150 million | 4.700% | Interest due semi annually, not subject to amortization, aggregate principal due on February 1, 2043 |

Credit Ratings

Two major corporate debt-rating organizations, Moody's and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

Table of Contents

The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured non-credit-enhanced long-term debt:

| Name of Rating Agency | Commercial | | | Date of Last Action |
|-----------------------|--------------|-----------------------|---------|---------------------|
| | Paper Rating | Long-term Debt Rating | Outlook | |
| Moody's | P-2 | Baa2 | Stable | January 2013 |
| S&P | A-3 | BBB- | Stable | January 2013 |

Pension Obligations

As part of the Separation, Pfizer transferred to us the net pension obligation of \$25 million associated with certain international defined benefit plans in the first quarter of 2013. We expect to contribute a total of approximately \$9 million to the plans in 2013. In the second quarter of 2013, a net liability of approximately \$16 million was recognized for the pension obligations less the fair value of plan assets associated with additional defined benefit pension plans in certain international locations that will be transferred to us in 2014, in accordance with the applicable local separation agreements.

Effective December 31, 2012, our employees ceased to participate in the Pfizer U.S. qualified defined benefit and U.S. retiree medical plans, and liabilities associated with our employees under these plans were retained by Pfizer. As part of the Separation, Pfizer is continuing to credit certain employees' service with Zoetis generally through December 31, 2017 (or termination of employment from Zoetis, if earlier) for certain early retirement benefits with respect to Pfizer's U.S. defined benefit pension and retiree medical plans. In connection with the employee matters agreement, Zoetis will be responsible for payment of three-fifths of the total cost of the service credit continuation (approximately \$38 million) for these plans. The amount of the service cost continuation payment to be paid by Zoetis to Pfizer was determined and fixed based on an actuarial assessment of the value of the grow-in benefits and will be paid in equal installments over a period of 10 years.

In the second quarter of 2013, Pfizer transferred to us the U.S. supplemental savings plan liability of approximately \$14 million, cash of \$9 million and a deferred tax asset of \$5 million associated with employees transferred to us as part of the Separation.

For additional information, see Notes to Condensed Consolidated and Combined Financial Statements—Note 12. Benefit Plans.

Off-balance sheet arrangements

In the ordinary course of business and in connection with the sale of assets and businesses, we may indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to activities prior to a transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters, and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 29, 2013 or December 31, 2012, recorded amounts for the estimated fair value of these indemnifications are not significant.

New accounting standards

For discussion of our new accounting standards, see Notes to Condensed Consolidated and Combined Financial Statements—Note 4A. Significant Accounting Policies: New Accounting Standards.

Recently Issued Accounting Standards, Not Adopted as of September 29, 2013

In July 2013, the Financial Accounting Standards Board (FASB) issued an accounting standards update regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, this unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard are effective January 1, 2014 for annual and interim reporting periods, but we do not expect the provisions of

this standard to have a significant impact on our consolidated financial statements.

In March 2013, the Financial Accounting Standards Board (FASB) issued an accounting standards update regarding the accounting for cumulative translation adjustment (CTA) upon derecognition of assets or investment within a foreign entity. This new standard provides additional CTA accounting guidance on sales or transfers of foreign entity investments and assets as well as step acquisitions involving a foreign entity. The provisions of the new standard are effective January 1, 2014, but we do not expect the provisions of this standard to have a significant impact on our consolidated financial statements.

In February 2013, the FASB issued an accounting standards update regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings. The provisions of this standard require that these obligations are measured at the amount representing the agreed upon obligation of the company as well as additional liability amounts it expects to assume on behalf of other parties in the arrangement. The provisions of the new standard are effective January 1, 2014, but we do not expect the provisions of this standard to have a significant impact on our consolidated financial statements.

Table of Contents

Forward-looking statements and factors that may affect future results

This report contains “forward-looking” statements. We generally identify forward-looking statements by using words such as “anticipate,” “estimate,” “expect,” “intend,” “project,” “plan,” “predict,” “believe,” “seek,” “continue,” “outlook,” “may,” “should,” “can have,” “likely” or the negative version of these words or comparable words or by using future dates in connection with any discussion of future performance, actions or events.

In particular, forward-looking statements include statements relating to the Separation, our indebtedness, our ability to make interest and principal payments on our indebtedness, our ability to satisfy the covenants contained in our indebtedness, the redemption of the notes, new systems infrastructure stand-up, our 2013 financial guidance, future actions, business plans or prospects, prospective products, product approvals or products under development, product supply disruptions, R&D costs, timing and likelihood of success, future operating or financial performance, future results of current and anticipated products and services, strategies, sales efforts, expenses, production efficiencies, production margins, interest rates, foreign exchange rates, growth in emerging markets, the outcome of contingencies, such as legal proceedings, dividend plans, our agreements with Pfizer, government regulation and financial results. These statements are not guarantees of future performance, actions or events. Forward-looking statements are subject to risks and uncertainties, many of which are beyond our control, and are potentially inaccurate assumptions. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

- emerging restrictions and bans on the use of antibacterials in food-producing animals;
- perceived adverse effects on human health linked to the consumption of food derived from animals that utilize our products;
- increased regulation or decreased governmental support relating to the raising, processing or consumption of food-producing animals;
- changes in tax laws and regulation;
- an outbreak of infectious disease carried by animals;
- adverse weather conditions and the availability of natural resources;
- adverse global economic conditions;
- failure of our R&D, acquisition and licensing efforts to generate new products;
- quarterly fluctuations in demand and costs;
- failure to achieve the expected benefits of the Separation and the Exchange Offer, which include improved strategic and operational efficiency, the adoption of a capital structure and investment and dividend policies that are designed for our standalone company, the use of our equity to facilitate future acquisitions and improved alignment of employee incentives with our performance and growth objectives;
- operation as a standalone public company without many of the resources previously available to us as a business unit of Pfizer;
- actual or potential conflicts of interest as a result of the fact that one of our directors will simultaneously serve as an employee of Pfizer; and
- governmental laws and regulations affecting domestic and foreign operations, including without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals.

However, there may also be other risks that we are unable to predict at this time. These risks or uncertainties may cause actual results to differ materially from those contemplated by a forward-looking statement. You should not put undue reliance on forward-looking statements. Forward-looking statements speak only as of the date on which they are made. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Form 10-Q and 8-K reports and our other filings with the SEC. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the above to be a complete discussion of all potential risks or uncertainties.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A significant portion of our revenue and costs are exposed to changes in foreign exchange rates. In addition, our outstanding borrowings may be subject to risk from changes in interest rates and foreign exchange rates. The overall objective of our financial risk management program is to seek to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and by using certain financial instruments. These practices may change as economic conditions change.

52 |

Foreign exchange risk

Our primary net foreign currency translation exposures are the euro, Brazilian real and Australian dollar. Prior to the IPO, as a business unit of Pfizer and under Pfizer's global cash management system, our foreign exchange risk was managed through Pfizer. Following the Separation, we seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities.

Foreign exchange risk is also managed through the use of foreign currency forward-exchange contracts. These contracts are used to offset the potential earnings effects from mostly intercompany short-term foreign currency assets and liabilities that arise from operations.

Our financial instrument holdings at September 29, 2013 were analyzed to determine their sensitivity to foreign exchange rate changes. The fair values of these instruments were determined using Level 2 inputs. For additional details, see Notes to Condensed Consolidated and Combined Financial Statements—Note 4B. Significant Accounting Policies: Fair Value. The sensitivity analysis of changes in the fair value of all foreign currency forward-exchange contracts at September 29, 2013 indicates that if the U.S. dollar were to appreciate against all other currencies by 10%, the fair value of these contracts would increase by \$40 million, and if the U.S. dollar were to weaken against all other currencies by 10%, the fair value of these contracts would decrease by \$38 million. For additional details, see Notes to Condensed Consolidated and Combined Financial Statements—Note 9E. Financial Instruments: Derivative Financial Instruments.

Interest rate risk

Our outstanding debt balances are fixed rate debt. While changes in interest rates will have no impact on the interest we pay on our fixed rate debt, interest on our revolving credit facility will be exposed to interest rate fluctuations. At September 29, 2013, we had no outstanding principal balance under our credit facility. See Notes to Condensed Consolidated and Combined Financial Statements—Note 9. Financial Instruments.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

An evaluation was carried out under the supervision and with the participation of the company's management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation as of September 29, 2013, our Chief Executive Officer and Chief Financial Officer each concluded that, as of the end of such period, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported on a timely basis, and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls over Financial Reporting

This report does not include management's assessment regarding changes in internal control over financial reporting due to a transition period established by rules of the SEC for newly public companies.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

The information required by this Item is incorporated herein by reference to Notes to Condensed Consolidated and Combined Financial Statements—Note 15. Commitments and Contingencies in Part I, Item 1, of this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors

In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in the "Our Operating Environment" and "Forward-Looking Information and Factors That May Affect Future Results" sections of the MD&A and in Part I, Item 1A. "Risk Factors," of our 2012 Annual Report on Form 10-K, which could materially affect our business, financial condition, or future results and which are incorporated by reference herein. Set forth below are updates to certain of the risk factors disclosed in our 2012 Annual Report on Form 10-K.

Animal health products are subject to unanticipated safety, quality or efficacy concerns, which may harm our reputation.

Unanticipated safety, quality or efficacy concerns can arise with respect to animal health products, whether or not scientifically or clinically supported, leading to product recalls, withdrawals or suspended or declining sales, as well as product liability and other claims. For example, as a result of safety concerns related to our product, PregSure BVD, in 2010, we voluntarily suspended sales of the product and withdrew the marketing authorization in the European Union (EU) and, in 2011, we suspended sales and withdrew the marketing authorization for the product in New Zealand. Also, in May 2013, we were advised that the European Commission started a procedure regarding the EU marketing authorization for Suvaxyn PCV, a vaccine against Porcine Circovirus 2 in swine. The initiation of the procedure followed a recall of two batches of Suvaxyn PCV as a result of higher than expected adverse reactions, reported mainly in Spain. In June, we completed a root cause investigation of the higher than expected adverse reactions in these two batches, and subsequently submitted to the European Medicines Agency (EMA) a proposed variation to describe specific adjustments to the manufacturing process to help minimize the risk of future reactive batches. In October, the EMA's Committee on Medicinal Products for Veterinary Use adopted a positive opinion as to the proposed variation and concurrently adopted an opinion concluding that no action was required at this time with regard to the EU marketing authorization for Suvaxyn PCV. Both opinions were transmitted to the European Commission according to the applicable procedure and we expect that they will be approved by the Commission in November.

Regulatory actions based on these types of safety, quality or efficacy concerns could impact all or a significant portion of a product's sales and could, depending on the circumstances, materially adversely affect our operating results. In addition, since we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products generally, by our customers, veterinarians and end-users, any concerns as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns and the related harm to our reputation could materially adversely affect our operating results and financial condition, regardless of whether such reports are accurate.

Risks related to our relationship with Pfizer

We may not achieve some or all of the expected benefits of the Separation and Exchange Offer.

We may not be able to achieve the full strategic and financial benefits expected to result from the Separation and Exchange Offer, or such benefits may be delayed or not occur at all. These expected benefits include the following: improving strategic and operational flexibility, increasing management focus and streamlining decision-making by providing the flexibility to implement our strategic plan and to respond more effectively to different customer needs and the changing economic environment;

- allowing us to adopt the capital structure, investment policy and dividend policy best suited to our financial profile and business needs, without competing for capital with Pfizer's other businesses;

- creating an independent equity structure that will facilitate our ability to effect future acquisitions utilizing our common stock; and

-

facilitating incentive compensation arrangements for employees more directly tied to the performance of our business, and enhancing employee hiring and retention by, among other things, improving the alignment of management and employee incentives with performance and growth objectives of our business.

We may not achieve the anticipated benefits of the Separation and the Exchange Offer for a variety of reasons, which could adversely affect our operating results and financial condition.

As a result of the Separation, we no longer benefit from Pfizer's brand, reputation, capital base and other resources. Prior to the IPO, as a business unit of Pfizer, we generally used the name "Pfizer Animal Health," and we believe the association with Pfizer and Pfizer's globally recognized brand and perceived high-quality products contributed to our ability to build relationships with our customers. Our loss of the use of the "Pfizer" name could adversely affect our ability to attract and retain customers, which could result in reduced sales of our products, and could impact our ability to attract and retain colleagues, which could result in extended vacancies in key or critical positions.

The loss of Pfizer's scale, capital base and financial strength may also prompt suppliers to reprice, modify or terminate their relationships with us. In addition, our separation from Pfizer may cause some of our existing agreements and licenses to be terminated. We cannot predict with

certainty the effect the Separation or the Exchange Offer may have on our business, our clients, vendors or other persons, or whether our new brand, Zoetis, will be accepted in the marketplace.

Pfizer may compete with us.

Pfizer is not restricted from competing with us in the animal health business, including as a result of acquiring a company that operates an animal health business. Due to the significant resources of Pfizer, including financial resources, name recognition and know-how resulting from the previous management of our business, Pfizer could have a significant competitive advantage over us should it decide to engage in the type of business we conduct, which may cause our operating results and financial condition to be materially adversely affected.

Certain of our directors may have actual or potential conflicts of interest because of their positions with Pfizer.

Certain of our directors are employed by Pfizer or may own Pfizer common stock, options to purchase Pfizer common stock or other Pfizer equity awards. Certain of these holdings may be individually significant to these directors as compared with such director's total assets. These directors' positions at Pfizer and the ownership of any Pfizer equity or equity awards create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for Pfizer than for us.

To preserve the tax-free treatment to Pfizer and/or its stockholders of the Exchange Offer and certain related transactions, we may not be able to engage in certain transactions.

To preserve the tax-free treatment to Pfizer and/or its stockholders of the Exchange Offer and certain related transactions, under the tax matters agreement, we are restricted from taking any action that prevents such transactions from being tax-free for U.S. federal, state, local and foreign income tax purposes. These restrictions may limit our ability to pursue certain strategic transactions or engage in other transactions, including taking certain actions with respect to our 3.250% Senior Notes due 2023 and using our common stock to make acquisitions in connection with equity capital market transactions that might increase the value of our business. See Note 17B. Transactions and Agreements With Pfizer: Agreements with Pfizer.

The assets and resources that we acquired from Pfizer in the separation may not be sufficient for us to operate as a standalone company, and we may experience difficulty in separating our assets and resources from Pfizer.

Because we have not operated as a standalone company in the past, we may have difficulty doing so. We may currently need, and in the future will be required, to acquire assets and resources separate from those provided to us by Pfizer, and in connection with the Separation we may also face difficulty in separating our assets from Pfizer's assets and integrating newly acquired assets into our business. Our business, financial condition and results of operations could be harmed if we have difficulty operating as a standalone company, fail to acquire assets that prove to be important to our operations or incur unexpected costs in separating our assets from Pfizer's assets or integrating newly acquired assets.

We may not be able to fully realize the expected benefits of our R&D agreement with Pfizer.

Prior to the Separation, as a business unit of Pfizer, we had the ability to leverage Pfizer's proprietary compound library and database to identify, research and develop compounds suitable as new product candidates for the animal health field. As part of the Separation, we entered into an R&D collaboration and license agreement with Pfizer, which is referred to as the "R&D agreement." Pursuant to the R&D agreement, subject to certain restrictions, we will have continued access to Pfizer's compound library and database for a period of seven years from the Separation date and will have, subject to Pfizer's approval, the possibility to exclusively license compounds from Pfizer that we develop under the R&D agreement.

While the R&D agreement is intended to bolster our post-Separation R&D capabilities, certain terms of the R&D agreement may limit our ability to achieve this expected benefit, including:

Pfizer will retain ownership of, and license to us, the intellectual property that we develop under the R&D agreement. In many circumstances, the intellectual property we license from Pfizer will be non-exclusive as to Pfizer and third parties.

We are not assured access to Pfizer's newest programs.

Pfizer can prevent us from progressing pre-development compounds and, under certain circumstances, Pfizer may terminate our rights to a development stage compound by paying us the fair market value for such compound.

The R&D agreement may be terminated before the expiration of the seven year term in certain circumstances, including if we acquire an interest in or assets of a human pharmaceutical business, enters into a definitive agreement

relating to or undergo a change of control, or Pfizer acquires, or is acquired by, an animal health business.

Each of the foregoing terms and Pfizer's other rights under the R&D agreement and related licenses (if any), could limit our ability to realize the expected benefits of the R&D agreement. If we fail to achieve the expected benefits of the R&D agreement, it may be more difficult, time consuming or expensive for us to develop and commercialize certain new products, or it may result in our products being later to market than those of our competitors. We may experience delays in new product development, which may result in our loss of the first-in-class products in a given therapeutic area.

For a summary description of the terms of the R&D collaboration and license agreement, see Note 17B. Transactions and Agreements with Pfizer: Agreements with Pfizer.

Pfizer's rights as licensor under the patent and know-how license could limit our ability to develop and commercialize certain products.

Under the patent and know-how license agreement (Pfizer as licensor) (the Patent and Know-How License Agreement), Pfizer licenses to us certain of its intellectual property. If we fail to comply with our obligations under this license agreement and Pfizer exercises its right to

terminate it, our ability to continue to research, develop and commercialize products incorporating that intellectual property will be limited. In addition, in circumstances where Pfizer has an interest in the licensed intellectual property in connection with its human health development programs, our rights to use the licensed intellectual property are restricted and/or in limited instances, subject to Pfizer's right to terminate such license at will. These limitations and termination rights may make it more difficult, time consuming or expensive for us to develop and commercialize certain new products, or may result in our products being later to market than those of our competitors.

For a summary description of the terms of the patent and know-how license (Pfizer as licensor), see Note 17B.

Transactions and Agreements with Pfizer: Agreements with Pfizer.

We are dependent on Pfizer to prosecute, maintain and enforce certain intellectual property.

Under the Patent and Know-How License Agreement, Pfizer is responsible for filing, prosecuting and maintaining patents that Pfizer licenses to us. In the animal health field, Pfizer has the first right, and in some cases the sole right, to enforce such licensed patents, and in the human health field, subject to certain exceptions, Pfizer has the sole right to enforce the licensed patents. If Pfizer fails to fulfill its obligations or chooses to not enforce the licensed patents under this agreement, we may not be able to prevent competitors from making, using and selling competitive products, which could have an adverse effect on our business.

Our historical combined financial data is not necessarily representative of the results we would have achieved as a standalone company and may not be a reliable indicator of our future results.

Our historical combined financial data included in this prospectus does not reflect the financial condition, results of operations or cash flows we would have achieved as a standalone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:

• Our historical combined financial data does not reflect the Separation;

• Our historical combined financial data (except for a portion of the 2013 first quarter data that was recorded since the date of the IPO) reflects expense allocations for certain support functions that are provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, business development, public affairs and procurement, as well as certain manufacturing and supply costs incurred by manufacturing sites that were shared with other Pfizer business units that may be higher or lower than the comparable expenses we would have actually incurred, or will incur, as a standalone company;

• Our cost of debt and our capital structure will be different from that reflected in our historical combined financial statements;

• Significant increases may occur in our cost structure as a result of our being a standalone public company, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and

• Loss of economies of scale as a result of our no longer being a part of Pfizer.

Our financial condition and future results of operations, after giving effect to the Separation, will be materially different from amounts reflected in our historical combined financial statements included in this prospectus. As a result of the Separation, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business.

We have incurred and will continue to incur significant charges in connection with the Separation and incremental costs as a standalone public company.

We will need to replicate or replace certain functions, systems and infrastructure to which we no longer have the same access after the Separation. We may also need to make investments or hire additional employees to operate without the same access to Pfizer's existing operational and administrative infrastructure. These initiatives may be costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change.

Prior to the Separation, Pfizer performed or supported many important corporate functions for our company. Our combined financial statements reflect charges for these services on an allocation basis. Following the Separation, many of these services will be governed by our transitional services agreement with Pfizer. Under the transitional services agreement we are able to use these Pfizer services for a fixed term established on a service-by-service basis.

However, we generally have the right to terminate a service earlier if we give notice to Pfizer. Partial reduction in the provision of any service requires Pfizer's consent. In addition, either party is able to terminate the agreement due to a material breach of the other party, upon prior written notice, subject to limited cure periods.

We pay Pfizer mutually agreed-upon fees for these services, based on Pfizer's costs of providing the services. During the two years following the IPO, the markup for these services will be 0% and, for the remainder of the term of the agreement, Pfizer may introduce a markup of 7%, which we believe is consistent with arm's length pricing for the services provided. However, since our transitional services agreement was negotiated in the context of a parent-subsiary relationship, the terms of the agreement, including the fees charged for the services, may be higher or lower than those that would be agreed to by parties bargaining at arm's length for similar services and may be higher or lower than the costs reflected in the allocations in our historical financial statements. Third party costs are passed through to us at Pfizer's or its affiliates' cost. In addition, while these services are being provided to us by Pfizer, our operational flexibility to modify or implement changes with respect to such services or the amounts we pay for them is limited.

We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including cost, comparable to those that we receive from Pfizer under our transitional services agreement.

Additionally, after the agreement terminates, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Pfizer. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable

to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Pfizer, which may not be addressed in our transitional services agreement. The level of this informal support may diminish or be eliminated in the future.

If there is a later determination that the Exchange Offer or certain related transactions are taxable for U.S. federal income tax purposes because the facts, assumptions, representations or undertakings underlying the IRS private letter ruling and/or any tax opinion are incorrect or for any other reason, then Pfizer and its stockholders could incur significant U.S. federal income tax liabilities, and we could incur significant liabilities.

Pfizer has received a private letter ruling from the IRS substantially to the effect that, among other things, the Exchange Offer will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the U.S. Internal Revenue Code of 1986 (the Code). Completion by Pfizer of the Exchange Offer was conditioned on, among other things, the continuing application of Pfizer's private letter ruling from the IRS and the receipt of an opinion of tax counsel, to the effect that, among other things, the Exchange Offer will qualify as a transaction that is tax-free for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Code. The ruling and the opinion rely on certain facts, assumptions, representations and undertakings from Pfizer and us regarding the past and future conduct of the companies' respective businesses and other matters. If any of these facts, assumptions, representations or undertakings are incorrect or not otherwise satisfied, Pfizer and its stockholders may not be able to rely on the ruling or the opinion of tax counsel and could be subject to significant tax liabilities. Notwithstanding the private letter ruling and opinion of tax counsel, the IRS could determine on audit that the Exchange Offer or certain related transactions are taxable if it determines that any of these facts, assumptions, representations or undertakings are not correct or have been violated or if it disagrees with the conclusions in the opinion that are not covered by the private letter ruling, or for other reasons, including as a result of certain significant changes in the stock ownership of Pfizer or us after the Exchange Offer. If the Exchange Offer or certain related transactions are determined to be taxable for U.S. federal income tax purposes, Pfizer and/or its stockholders could incur significant U.S. federal income tax liabilities, and we could incur significant liabilities under applicable law or under the tax matters agreement.

Risks Related to Zoetis Common Stock

The price of our common stock may fluctuate substantially, and you could lose all or part of your investment in Zoetis common stock as a result.

Our common stock has a limited trading history and there may be wide fluctuations in the market value of our common stock as a result of many factors. From our IPO through September 29, 2013, the sales price of our common stock as reported by the New York Stock Exchange has ranged from a low sales price of \$28.81 on August 28, 2013 to a high sales price of \$35.42 on March 14, 2013. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this section and in our 2012 Annual Report, are:

- our operating performance and the performance of our competitors;
- our or our competitors' press releases, other public announcements and filings with the SEC regarding new products or services, enhancements, significant contracts, acquisitions or strategic investments;
- changes in earnings estimates or recommendations by securities analysts, if any, who cover our common stock;
- changes in our investor base;
- failures to meet external expectations or management guidance;
- fluctuations in our financial results or the financial results of companies perceived to be similar to us;
- changes in our capital structure or dividend policy, including as a result of the Exchange Offer, future issuances of securities, sales of large blocks of common stock by our stockholders or the incurrence of additional debt;
- reputational issues;
- changes in general economic and market conditions in any of the regions in which we conduct our business;
- the arrival or departure of key personnel;
- the actions of speculators and financial arbitrageurs (such as hedge funds) during and after the Exchange Offer;
- changes in applicable laws, rules or regulations and other dynamics; and
- other developments or changes affecting us, our industry or our competitors.

In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

While we currently intend to pay a quarterly cash dividend to our common stockholders, we may change our dividend policy at any time.

On September 12, 2013, our Board of Directors declared the 2013 fourth quarter dividend of \$0.065 per share to be paid on December 2, 2013 to holders of record on November 1, 2013. Although we currently intend to pay a quarterly cash dividend to our common stockholders, we have no obligation to do so, and our dividend policy may change at any time without notice to our stockholders. Returns on stockholders' investments will primarily depend on the appreciation, if any, in the price of our common stock. We anticipate that we will retain most of our future earnings, if any, for use in the development and expansion of our business, repayment of indebtedness and for general corporate purposes. The declaration

57 |

and payment of dividends is at the discretion of our Board of Directors in accordance with applicable law after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, cash flows available in the U.S., impact on our effective tax rate, indebtedness, legal requirements and other factors that our Board of Directors deems relevant.

Provisions in our amended and restated certificate of incorporation, amended and restated by-laws and Delaware law may prevent or delay an acquisition of us, which could decrease the trading price of our common stock.

Our amended and restated certificate of incorporation, which we refer to as “our certificate of incorporation,” and amended and restated by-laws, which we refer to as “our by-laws,” contain provisions that are intended to deter coercive takeover practices and inadequate takeover bids and to encourage prospective acquirers to negotiate with our Board of Directors rather than to attempt a hostile takeover. These provisions include:

- a Board of Directors that is divided into three classes with staggered terms;
- rules regarding how our stockholders may present proposals or nominate directors for election at stockholder meetings;

- the right of our Board of Directors to issue preferred stock without stockholder approval; and

- limitations on the right of stockholders to remove directors.

In addition, Delaware law also imposes some restrictions on mergers and other business combinations between us and any holder of 15% or more of our outstanding common stock. These provisions apply even if the offer may be considered beneficial by some stockholders and could delay or prevent an acquisition that our Board of Directors determines is not in our and our stockholders' best interests.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

Edgar Filing: Zoetis Inc. - Form 10-Q

Item 6. Exhibits

| | |
|--------------|---|
| Exhibit 3.1 | Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to Zoetis Inc.'s Annual Report on Form 10-K 2012 filed on March 28, 2013) |
| Exhibit 3.2 | Amended and Restated By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to Zoetis Inc.'s Annual Report on Form 10-K 2012 filed on March 28, 2013) |
| Exhibit 10.1 | Non-Employee Director Deferred Compensation Plan (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K, filed with the SEC on May 7, 2013) |
| Exhibit 10.2 | Zoetis Supplemental Savings Plan (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form S-8, filed with the SEC on June 25, 2013) |
| Exhibit 12 | Computation of Ratio of Earnings to Fixed Charges |
| Exhibit 15 | Accountants' Acknowledgment |
| Exhibit 31.1 | Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 |
| Exhibit 31.2 | Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 302 |
| Exhibit 32.1 | Chief Executive Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 |
| Exhibit 32.2 | Chief Financial Officer–Certification pursuant to Sarbanes-Oxley Act of 2002 Section 906 |
| EX-101.INS | INSTANCE DOCUMENT |
| EX-101.SCH | SCHEMA DOCUMENT |
| EX-101.CAL | CALCULATION LINKBASE DOCUMENT |
| EX-101.LAB | LABELS LINKBASE DOCUMENT |
| EX-101.PRE | PRESENTATION LINKBASE DOCUMENT |
| EX-101.DEF | DEFINITION LINKBASE DOCUMENT |

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Zoetis Inc.

November 13, 2013

By: /S/ JUAN RAMÓN ALAIX
Juan Ramón Alaix
Chief Executive Officer and
Director

November 13, 2013

By: /S/ RICHARD A. PASSOV
Richard A. Passov
Chief Financial Officer

60 |